



```

APPLICANT: Welch, Roy
TITLE OF INVENTION: Nucleic Acid Detection
FILE REFERENCE: PRO-103 6868/5528
CURRENT APPLICATION NUMBER: US/09/358, 972
CURRENT FILING DATE: 1999-07-22
EARLIER APPLICATION NUMBER: 09/252, 436
EARLIER FILING DATE: 1999-02-18
EARLIER APPLICATION NUMBER: 09/042, 287
NUMBER OF SEQ ID NOS: 290
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO: 103
LENGTH: 30
TYPE: DNA
ORGANISM: Campylobacter jejuni
FEATURE:
OTHER INFORMATION: probe to Campylobacter jejuni
seq_name: /cgn2_6/ptodata/2/1na/6B_COMB.seq:US-09-406-147-32
; seq_documentation_block:
; Sequence 34 Application US/09406147
; Patent No. 627074
; GENERAL INFORMATION:
; APPLICANT: Shultz, John W
; APPLICANT: Lewis, Martin K
; APPLICANT: Leippe, Donna
; APPLICANT: Mandrekar, Michelle
; APPLICANT: Rhodes, Richard B
; APPLICANT: Andrews, Christine A
; APPLICANT: Hartnett, James R
; APPLICANT: Gu, Trent
; APPLICANT: Wood, Keith V
; APPLICANT: Welch, Roy
; TITLE OF INVENTION: EXOGENOUS NUCLEIC ACID DETECTION
; FILE REFERENCE: EXOGENOUS NUCLEIC ACID DETECTION
; CURRENT APPLICATION NUMBER: US/09/406,147
; CURRENT FILING DATE: 1999-09-27
; EARLIER APPLICATION NUMBER: 09/252, 436
; EARLIER FILING DATE: 1999-02-18
; EARLIER APPLICATION NUMBER: 09/042, 287
; EARLIER FILING DATE: 1999-03-13
; NUMBER OF SEQ ID NOS: 92
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO: 34
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Campylobacter jejuni
; US-09-406-147-34
; seq_name: /cgn2_6/ptodata/2/1na/6B_COMB.seq:US-09-406-147-32
; alignment_scores:
; alignment_block:
; Sequence 34 Application US/09406147
; Patent No. 627074
; GENERAL INFORMATION:
; APPLICANT: Shultz, John W
; APPLICANT: Lewis, Martin K
; APPLICANT: Leippe, Donna
; APPLICANT: Mandrekar, Michelle
; APPLICANT: Rhodes, Richard B
; APPLICANT: Andrews, Christine A
; APPLICANT: Hartnett, James R
; APPLICANT: Gu, Trent
; APPLICANT: Wood, Keith V
; APPLICANT: Welch, Roy
; TITLE OF INVENTION: EXOGENOUS NUCLEIC ACID DETECTION
; FILE REFERENCE: EXOGENOUS NUCLEIC ACID DETECTION
; CURRENT APPLICATION NUMBER: US/09/406,147
; CURRENT FILING DATE: 1999-09-27
; EARLIER APPLICATION NUMBER: 09/252, 436
; EARLIER FILING DATE: 1999-02-18
; EARLIER APPLICATION NUMBER: 09/042, 287
; EARLIER FILING DATE: 1999-03-13
; NUMBER OF SEQ ID NOS: 92
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO: 34
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Campylobacter jejuni
; US-09-406-147-32
; alignment_scores:
; alignment_block:
; Sequence 22 Application US/09130663A
; GENERAL INFORMATION:
; APPLICANT: Conklin, Darrell C.
; TITLE OF INVENTION: LIPOCALIN HOMOLOG
; FILE REFERENCE: 97-24
; CURRENT APPLICATION NUMBER: US/09/130, 663A
; CURRENT FILING DATE: 1998-08-05
; EARLIER APPLICATION NUMBER: 60/054, 867
; EARLIER FILING DATE: 1997-08-06
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO: 22
; alignment_scores:
; alignment_block:
; Sequence 22 Application US/09130663A
; Patent No. 6020163
; GENERAL INFORMATION:
; APPLICANT: Conklin, Darrell C.
; TITLE OF INVENTION: LIPOCALIN HOMOLOG
; FILE REFERENCE: 97-24
; CURRENT APPLICATION NUMBER: US/09/130, 663A
; CURRENT FILING DATE: 1998-08-05
; EARLIER APPLICATION NUMBER: 60/054, 867
; EARLIER FILING DATE: 1997-08-06
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO: 22

```

```

; LENGTH: 51
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE: OTHER INFORMATION: Oligonucleotide primer: 2C13735.
; US-09-130-663-22

alignment_scores:
    Quality: 43.00      Length: 16
    Ratio: 3.583        Gaps: 0
    Percent Similarity: 75.000   Percent Identity: 50.000
    alignment_block:
        US-09-439-311-2 x US-09-130-663-22

Align seg 1/1 to: US-09-130-663-22 from: 1 to: 51

seq_name: /cgn2_6/ptodata/2/1na/6A.COMB.seq:US-09-081-180-29
seq_documentation_block:
    Sequence 29, Application US/09081180
    Patent No. 602847
    GENERAL INFORMATION:
        APPLICANT: Sheppard, Paul O.
        ADDRESSEE: ZymoGenetics
        STREET: 1201 Eastlake Ave. E.
        CITY: Seattle
        STATE: WA
        COUNTRY: USA
        ZIP: 98102
    COMPUTER READABLE FORM:
        COMPUTER: IBM Compatible
        MEDIUM TYPE: Diskette
        OPERATING SYSTEM: DOS
    CURRENT APPLICATION DATA:
        SOFTWARE: FastSEQ for Windows Version 2.0
    FILING DATE:
        CLASSIFICATION:
        PRIORITY APPLICATION DATA:
            APPLICATION NUMBER: 60/041,263
            FILING DATE: March 19, 1997
        ATTORNEY/AGENT INFORMATION:
            NAME: Lingenfelter, Susan E
            REGISTRATION NUMBER: 41,156
            REFERENCE/DOCKET NUMBER: 97-17
    TELECOMMUNICATION INFORMATION:
        TELEPHONE: 206-442-6675
        TELEX: 206-442-6678
    INFORMATION FOR SEQ ID NO: 29:
    SEQUENCE CHARACTERISTICS:
        LENGTH: 51 base pairs
        TYPE: nucleic acid
        STRANDEDNESS: single
    TOPOLOGY: linear
    MOLECULE TYPE: cDNA
    IMMEDIATE SOURCE:
        CLONE: 2C13735
    INFORMATION FOR SEQ ID NO: 29:
    SEQUENCE CHARACTERISTICS:
        LENGTH: 16
        Quality: 43.00      Gaps: 0
        Ratio: 3.583        Percent Identity: 50.000
        Percent Similarity: 75.000   Percent Identity: 50.000
    alignment_block:
        US-09-439-311-2 x US-09-040-786-29

Align seg 1/1 to: US-09-040-786-29 from: 1 to: 51

```

253 GlyValValIleGlyIysvaAspTywserAspGlyIspGluasnGly 268  
 ||||| :::: |||| | | | | | | | | | | | | | | | | | | | | | |  
 1 GGGTAAAGCTTGACAAAGAGATTCACRAGGACGATGATGACAGGGT 48  
 seq\_name: /cgn2\_6/ptodata/2/1na/6A\_COMB.seq;US-09-432-335-22  
 seq\_documentation\_block:  
 Sequence 22, Application US/09432335  
 GENERAL INFORMATION:  
 PATENT NO. 6143720  
 APPLICANT: Conklin, Darrel C.  
 TITLE OF INVENTION: LIPOCALIN HOMOLOG  
 FILE REFERENCE:  
 CURRENT APPLICATION NUMBER: US/09432,335  
 CURRENT FILING DATE: 1999-11-02  
 EARLIER APPLICATION NUMBER: 09/130,663  
 EARLIER FILING DATE: 1998-08-06  
 EARLIER APPLICATION NUMBER: 60/054,867  
 EARLIER FILING DATE: 1997-08-06  
 NUMBER OF SEQ ID NOS: 30  
 SOFTWARE: FASTSEQ for Windows Version 3.0  
 SEQ ID NO. 22  
 LENGTH: 51  
 TYPE: DNA  
 ORGANISM: Artificial sequence  
 FEATURE:  
 OTHER INFORMATION: Oligonucleotide primer: ZC13735  
 US-09-432-335-22  
  
 alignment\_scores:  
 Quality: 43.00 Length: 16  
 Percent Similarity: 3.583 Gaps: 0  
 Percent Identity: 50.000  
  
 alignment\_block:  
 US-09-439-311-2 x US-09-432-335-22  
  
 Align seg 1/1 to: US-09-432-335-22 from: 1 to: 51  
  
 253 GlyValValIleGlyIysvaAspTywserAspGlyIspGluasnGly 268  
 ||||| :::: |||| | | | | | | | | | | | | | | | | | | | | | |  
 1 GCGTGTAAAGCTTGACAAAGAGATTCACRAGGACGATGACAGGGT 48  
  
 seq\_name: /cgn2\_6/ptodata/2/1na/5A\_COMB.seq;US-08-219-012-80  
  
 seq\_documentation\_block:  
 Sequence 80, Application US/08219012  
 Patent No. 5543293  
 GENERAL INFORMATION:  
 APPLICANT: Larry Gold  
 APPLICANT: Diane Tasset  
 TITLE OF INVENTION: Ligands of Thrombin  
 NUMBER OF SEQUENCES: 92  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Swanson & Bratschun, L.L.C.  
 STREET: 8400 E. Prentice Avenue, Suite 200  
 CITY: Englewood  
 STATE: Colorado  
 COUNTRY: USA  
 ZIP: 80111  
  
 COMPUTER READABLE FORM:  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: DISKETTE, 3.5 inch, 1.44 MB storage  
 COMPUTER: IBM compatible  
 OPERATING SYSTEM: MS-DOS  
 SOFTWARE: WordPerfect 6.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/687,421  
 FILING DATE: 08-MAY-1996  
 CLASSIFICATION: 435  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 08/195,005  
 FILING DATE: 10-APRIL-1994  
 CLASSIFICATION: 435  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 08/219,012  
 FILING DATE: 28-MARCH-1994  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 07/973,333  
  
 NAME: Barry J. Swanson  
 REGISTRATION NUMBER: 33,215  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (303) 850-9900  
 TELEFAX: (303) 850-9401  
 INFORMATION FOR SEQ ID NO: 80:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 60 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 US-08-219-012-80  
  
 alignment\_scores:  
 Quality: 40.00 Length: 19  
 Percent Similarity: 2.667 Gaps: 0  
 Percent Identity: 42.105  
  
 alignment\_block:  
 US-09-439-311-2 x US-08-219-012-80  
  
 Align seg 1/1 to: US-08-219-012-80 from: 1 to: 60  
  
 204 ThrSerValGlyIleGlyIleGlyIleAlaGluGluIleAsnGAS 226  
 |||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:  
 4 ACCGGGAGGGCTAGGGTTGGAGGCCatGTGCTAGGCACCGGA 53  
 220 nalaASP 222  
 ::::|||:  
 54 CTCGGAT 60  
  
 seq\_name: /cgn2\_6/ptodata/2/1na/6B\_COMB.seq;US-08-687-421-268  
  
 seq\_documentation\_block:  
 Sequence 268, Application US/08687421  
 PATENT NO. 617757  
 GENERAL INFORMATION:  
 APPLICANT: Gold, Larry  
 APPLICANT: Janjic, Nebojsa  
 APPLICANT: Tasset, Diane  
 TITLE OF INVENTION: HIGH-AFFINITY LIGANDS OF BASIC  
 TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR AND  
 TITLE OF INVENTION: THROMBIN  
 NUMBER OF SEQUENCES: 445  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Swanson & Bratschun, L.L.C.  
 STREET: 8400 E. Prentice Avenue, Suite 200  
 CITY: Englewood  
 STATE: Colorado  
 COUNTRY: USA  
 ZIP: 80111  
  
 COMPUTER READABLE FORM:  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: DISKETTE, 3.5 inch, 1.44 MB storage  
 COMPUTER: IBM compatible  
 OPERATING SYSTEM: MS-DOS  
 SOFTWARE: WordPerfect 6.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/687,421  
 FILING DATE: 08-MAY-1996  
 CLASSIFICATION: 435  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 08/195,005  
 FILING DATE: 10-APRIL-1994  
 CLASSIFICATION: 435  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 08/219,012  
 FILING DATE: 28-MARCH-1994  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 07/973,333

```

; FILING DATE: 11-NOVEMBER-1992
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 07/714,131
; FILING DATE: 10-JUNE-1991
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 07/536,428
; FILING DATE: 11-JUNE-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: BARRY J. SWARSON
; REGISTRATION NUMBER: 33,215
; REFERENCE/DOCKET NUMBER: NEX07/PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (303) 793-3333
; TELEFAX: (303) 793-3433
; INFORMATION FOR SEQ ID NO: 268:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 60 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-687-421-268

; alignment_scores:
; Quality: 40.00 Length: 19
; Ratio: 2.667 Gaps: 0
; Percent Similarity: 78.947 Percent Identity: 42.105

; alignment_block:
; alignment_block:
; Align seg 1/1 to: US-08-687-421-268 ..
; seq_name: /seqn_2_5/ptodata/2/ina/5A_COMB.seq:US-08-482-882-97

; seq_documentation_block:
; Sequence 97, Application US/08482882
; Patent No. 5773218
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemary
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606

; COMPUTER READABLE FORM:
; COMPUTER TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/482,882
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US 08/286,754
; FILING DATE:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIORITY APPLICATION DATA:

; alignment_scores:
; Quality: 40.00 Length: 19
; Ratio: 2.667 Gaps: 0
; Percent Similarity: 78.947 Percent Identity: 42.105

; alignment_block:
; alignment_block:
; Align seg 1/1 to: US-08-687-421-268 ..
; seq_name: /seqn_2_5/ptodata/2/ina/5A_COMB.seq:US-08-482-882-97

; seq_documentation_block:
; Sequence 97, Application US/08482882
; Patent No. 5773218
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemary
; TITLE OF INVENTION: ICAM-RELATED PROTEIN
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 233 South Wacker Drive/6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,389
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIORITY APPLICATION DATA:

; alignment_scores:
; Quality: 39.00 Length: 12
; Ratio: 3.900 Gaps: 0
; Percent Similarity: 83.333 Percent Identity: 66.667

; alignment_block:
; alignment_block:
; Align seg 1/1 to reverse of: US-08-482-882-97/rev ..
; seq_name: /cgn2_6/ptodata/2/ina/5A_COMB.seq:US-08-483-389-97

; seq_documentation_block:
; Sequence 97, Application US/08483389
; Patent No. 5811517
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemary
; TITLE OF INVENTION: ICAM-RELATED PROTEIN
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 233 South Wacker Drive/6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,389
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIORITY APPLICATION DATA:

```

APPLICATION NUMBER: US 08/009, 266  
 FILING DATE: 22-JAN-1993  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US 07/894, 061  
 FILING DATE: 05-JUN-1992  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US 07/889, 724  
 FILING DATE: 27-JAN-1992  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Suh, Young J.  
 REGISTRATION NUMBER: P-41, 337  
 REFERENCE/DOCKET NUMBER: 27866/32760  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (312) 474-6300  
 TELEFAX: (312) 474-0448  
 TELEX: (312) 474-6600  
 INFORMATION FOR SEQ ID NO: 97:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 47 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: DNA  
 US-08-483-389-97

\* alignment\_scores:  
 Quality: 39.00 Length: 12  
 Ratio: 3.900 Gaps: 0  
 Percent Similarity: 83.333 Percent Identity: 66.667

alignment\_block:  
 US-09-439-311-2 x US-08-483-389-97/rev . .

Align seq 1/1 to reverse of: US-08-483-389-97 from: 1 to: 47

169 ArgPheGluThrGlySerGlnSerPheSerSerGly 180  
 ||:::||||||| ||||| ||:::|||||||  
 44 AGGTGGAGACTGGTCAGCACGAGTTGGAGGAGGA 9

seq\_name: /cgn2\_6/ptodata/2/1na/5B\_COMB.seq:US-08-487-113D-97

seq\_documentation\_block:  
 Sequence 97, Application US/08487113D  
 ; Patent No. 5837822

GENERAL INFORMATION:  
 APPLICANT: Gallatin, W. Michael  
 APPLICANT: Vazeux, Rosemary  
 TITLE OF INVENTION: ICAM-Related Materials and Methods  
 NUMBER OF SEQUENCES: 120

CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
 STREET: 6300 Sears Tower, 233 South Wacker Drive  
 CITY: Chicago  
 STATE: Illinois  
 COUNTRY: United States of America  
 ZIP: 60606-6402

COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/487,113D  
 FILING DATE: 05-AUG-1994  
 CLASSIFICATION: 424

PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US 08/286, 754  
 FILING DATE: 07-JUN-1995  
 CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/102, 852  
 FILING DATE: 05-AUG-1993  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US 08/009, 266  
 FILING DATE: 22-JAN-1993  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US 07/894, 061  
 FILING DATE: 05-JUN-1992  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US 07/889, 724  
 FILING DATE: 26-MAY-1992  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US 07/827, 689  
 FILING DATE: 27-JAN-1992  
 ATTORNEY/AGENT INFORMATION:  
 NAME: NO. 5837822and, Greta E.  
 REGISTRATION NUMBER: 35,302  
 REFERENCE/DOCKET NUMBER: 32744  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (312) 474-6300  
 TELEFAX: (312) 474-0448  
 TELEX: 25-3856  
 INFORMATION FOR SEQ ID NO: 97:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 47 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: DNA  
 US-08-487-113D-97

\* alignment\_scores:  
 Quality: 39.00 Length: 12  
 Ratio: 3.900 Gaps: 0  
 Percent Similarity: 83.333 Percent Identity: 66.667

alignment\_block:  
 US-09-439-311-2 x US-08-487-113D-97/rev . .

Align seq 1/1 to reverse of: US-08-487-113D-97 from: 1 to: 47

169 ArgPheGluThrGlySerGlnSerPheSerSerGly 180  
 ||:::||||||| ||||| ||:::|||||||  
 44 AGGTGGAGACTGGTCAGCACGAGTTGGAGGAGGA 9

seq\_name: /cgn2\_6/ptodata/2/1na/5B\_COMB.seq:US-08-473-503-97

seq\_documentation\_block:  
 Sequence 97, Application US/08473503  
 ; Patent No. 5809262

GENERAL INFORMATION:  
 APPLICANT: Gallatin, W. Michael  
 APPLICANT: Vazeux, Rosemary  
 TITLE OF INVENTION: ICAM-Related Materials and Methods  
 NUMBER OF SEQUENCES: 116

CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
 STREET: 6300 Sears Tower, 233 S. Wacker Drive  
 CITY: Chicago  
 STATE: Illinois  
 COUNTRY: USA  
 ZIP: 60606

COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/473,503  
 FILING DATE: 07-JUN-1995  
 CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/286,754  
FILING DATE: 05-AUG-1994  
APPLICATION NUMBER: US 08/102,852  
FILING DATE: 05-AUG-1993  
PRIORITY APPLICATION DATA:  
FILING DATE: 22-JAN-1993  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: US 07/894,061  
FILING DATE: 05-JUN-1992  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: US 07/889,724  
FILING DATE: 26-MAY-1992  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: US 07/827,689  
FILING DATE: 27-JAN-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: NO. 5880268and, Greta E.  
REGISTRATION NUMBER: 35,302  
REFERENCE/DOCKET NUMBER: 32178  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (312) 474-6300  
TELEFAX: (312) 474-0448  
TELEX: 25-3856  
INFORMATION FOR SEQ ID NO: 97:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 47 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-473-503-97  
  
alignment\_scores:  
Percent Similarity: 39.00 Length: 12  
Ratio: 3.900 Gaps: 0  
Percent Identity: 66.667  
alignment\_block:  
US-09-439-311-2 x US-08-473-503-97/rev  
  
Align seq 1/1 to reverse of: US-08-473-503-97 from: 1 to: 47  
seq\_documentation\_block:  
; Sequence 97, Application US/08483932  
; Patent No. 5880268  
; GENERAL INFORMATION:  
; APPLICANT: Galatin, W. Michael  
; APPLICANT: Vazeux, Rosemary  
; TITLE OF INVENTION: ICM-Related Materials and Methods  
; NUMBER OF SEQUENCES: 116  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 S. Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: USA  
; ZIP: 60606  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: FLOPPY disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/483,932  
; FILING DATE: 07-JUN-1995  
  
CLASSIFICATION: 530  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: 08/286,754  
FILING DATE: 05-AUG-1994  
APPLICATION NUMBER: US 08/102,852  
FILING DATE: 05-AUG-1993  
PRIORITY APPLICATION DATA:  
FILING DATE: 22-JAN-1993  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: US 07/889,724  
FILING DATE: 26-MAY-1992  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: US 07/827,689  
FILING DATE: 27-JAN-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: NO. 5880268and, Greta E.  
REGISTRATION NUMBER: 35,302  
REFERENCE/DOCKET NUMBER: 32178  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (312) 474-6300  
TELEFAX: (312) 474-0448  
TELEX: 25-3856  
INFORMATION FOR SEQ ID NO: 97:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 47 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-483-932-97  
  
alignment\_scores:  
Percent Similarity: 39.00 Length: 12  
Ratio: 3.900 Gaps: 0  
Percent Identity: 66.667  
alignment\_block:  
US-09-439-311-2 x US-08-483-932-97/rev  
  
Align seq 1/1 to reverse of: US-08-483-932-97 from: 1 to: 47  
169 ArgPheGluThrGlySerGlnSerPheSerSerGly 180  
||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:  
44 AGGATGGAGACTGGTCAGCACGATTGGAGCGGA 9  
seq\_name: /egn2.6/ptodata/2/ina/5B\_COMB.seq;US-08-483-932-97  
  
169 ArgPheGluThrGlySerGlnSerPheSerSerGly 180  
||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:  
44 AGGATGGAGACTGGTCAGCACGATTGGAGCGGA 9

Wed Apr 17 07:36:49 2002

us-09-439-311-2.rni

Date: Apr 17, 2002 3:08 AM  
About: Results were produced by the Gencore software,  
Copyright (c) 1993-2000 Compugen Ltd.

30	ARR53100	Sequence 102 from patient
30	ARR53101	Sequence 103 from patient
30	A931655	Sequence 4 from patient
30	WC	
51	A1323	oligonucleotide 12/1993
51	A1324	oligonucleotide 12/1993
51	A15566	oligonucleotide 1/1994
51	A1597	oligonucleotide 1/1994
59	AIX11428	Sequence 105 from Patient
60	AR12529	Sequence 268 from patient
60	I24293	Sequence 80 from patient
47	AR13897	Sequence 97 from patient
47	AR13898	Sequence 97 from patient
47	AR042511	Sequence 97 from patient
47	AR058	Sequence 97 from patient
47	AR088217	Sequence 97 from patient
52	AF0163970	Saccharomyces cerevisiae
51	AX155673	Sequence 1 from Patent
51	AX158757	Sequence 2085 from Patent
51	AX158758	Sequence 2086 from Patent
51	AX158759	Sequence 2087 from Patent
53	AR009607	Sequence 3 from patient
53	AR036067	Sequence 3 from patient
53	I27657	Sequence 3 from patient
60	AX015223	Sequence 1 from Patent
24	AR001228	Sequence 6 from patient
24	AR08251	Sequence 6 from patient
24	AR01018	Sequence 6 from patient
24	AR064102	Sequence 6 from patient
41	I32911	Sequence 6 from patient
49	AR09123	Sequence 82 from patient
51	E31328	Process for producing nov
51	AIX158668	Sequence 1996 from Patent
51	AIX158963	Sequence 2291 from Patent
51	AIX158964	Sequence 2292 from Patent
51	AIX161669	Sequence 4997 from Patent
53	A174709	Nucleotide sequence 15 fr
60	AR02802	Sequence 4 from patient
60	AR01743	Sequence 5 from patient
60	L36603	Homo sapiens (PB-3 PA635)
34	A32410	Synthetic PNA-2 pdBp Link
34	AXI37684	Sequence 17 from patient

seq_name:	gb_pat:AR153100						
seq_documentation_block:							
LOCUS	AR153100	30	bp	DNA	PAT	08-AUG-2001	
DEFINITION	Sequence 102 from parent US 6235480.						
ACCESSION	AR153100						
VERSION	AR153100.1						
KEYWORDS							
SOURCE	.						
ORGANISM	Unknown.						
REFERENCE	Unclassified.						
AUTHORS	1 (bases 1 to 30)						
TITLE	Shultz, J. William, Lewis, M. K., Leippe, D., Mandrekar, M., Kephart, D., Rhodes, R. Byron, Andrews, C. Ann, Hartnett, J. Robert, Gu, T., Olson, R. J., Wood, K. V. and Welch, R.						
JOURNAL	Detection of nucleic acid hybrids						
FEATURES	Patent: US 6235480-A 102 22-MAY-2001.						
source	Location/Qualifiers						
BASE COUNT	1..30 /organism="unknown"						
ORIGIN	5 a 5 c 4 g 16 t						

US-09-439-311-2 x AR153101 ..

Align seg 1/1 to: AR153101 from: 1 to: 30

97 GlnaspGlylSerleuLysThrArgThr 105  
 |||||:|||||:|||||:|||||:|||||:  
 1 CAAGATGGACAAGATTAAACAGAACT 30

seq\_name: gb\_pat:A93365

LOCUS	A93365	DNA	PAT	22-JAN-2000
DEFINITION	Sequence 4 from Patent WO9744451.			
ACCESSION	A93365			
VERSION	A93365.1	GI:6741628		
KEYWORDS	unidentified			
ORGANISM	unclassified			
REFERENCE	1 (bases 1 to 50)			
AUTHORS	Paesen, G.C. and Nuttall, P.A.			
TITLE	WASOACTIVE AMINE BINDING MOLECULES			
JOURNAL	PATENT: WO 9744451-A 4 27-NOV-1997;			
FEATURES	OXFORD VACS LTD (GB); PAESEN GUIDO CHRISTIAN (GB) Location/Qualifiers			
SOURCE	1. .50 /organism="unidentified"			
BASE COUNT	11 a 8 c 14 g 17 t			
ORIGIN				

alignment\_scores:

Quality:	41.00	Length:	10
Ratio:	4.100	Gaps:	0

Percent Similarity: 100.000 Percent Identity: 70.000

alignment\_block:  
 US-09-439-311-2 x A93365 ..

Align seg 1/1 to: A93365 from: 1 to: 50

262 SeraspGlylAspGluAsnGlySerileuLe 271  
 |||||:|||||:|||||:|||||:  
 7 AGTGATGGATGATGATGGATCCCTCIG 36

seq\_name: gb\_pat:A12323

LOCUS	A12323	DNA	PAT	06-DEC-1993
DEFINITION	oligonucleotide.			
ACCESSION	A12323			
VERSION	A12323.1	GI:491330		
KEYWORDS				
SOURCE	synthetic construct.			
ORGANISM	artificial sequence.			
REFERENCE	1 (bases 1 to 51)			
AUTHORS				
TITLE	HYBRID PROTEINS OR POLYPEPTIDES			
JOURNAL	PATENT: WO 8802757-A 25 21-APR-1988;			
FEATURES	Location/Qualifiers			
SOURCE	1. .51 /organism="synthetic construct" /db_xref="taxon:32630"			
BASE COUNT	2 a 7 c 27 g 15 t			
ORIGIN				

alignment\_scores:

Quality:	41.00	Length:	17
Ratio:	3.154	Gaps:	0

Percent Similarity: 76.471 Percent Identity: 47.059

alignment\_block:  
 US-09-439-311-2 x A12324 ..

Align seg 1/1 to: A12324 from: 1 to: 51

300 GlyArgGlylAlaLysIleThrGlySerileGlylValGlyAlaGlyIle 316  
 |||||:|||||:|||||:|||||:  
 1 GGGATCGGGTTGGCTTGGGTTGGCTTGGGGTTGGCTTGGATCCT 50  
 316 u 316  
 51 c 51

seq\_name: gb\_pat:A12596

LOCUS	A12596	DNA	PAT	05-JAN-1994
DEFINITION	oligonucleotide.			
ACCESSION	A12596			
VERSION	A12596.1	GI:491421		
KEYWORDS				
SOURCE	synthetic construct.			
ORGANISM	synthetic construct.			
REFERENCE	artificial sequence.			
AUTHORS	1 (bases 1 to 51)			
TITLE	RECOMBINANT VIRUS			
JOURNAL	PATENT: WO 8701386-A 12 12-MAR-1987;			
FEATURES	Location/Qualifiers			
SOURCE	1. .51 /organism="synthetic construct"			
BASE COUNT	15 a 27 c 7 g 2 t			
ORIGIN				

alignment\_scores:

Quality:	41.00	Length:	17
Ratio:	3.154	Gaps:	0

Percent Similarity: 76.471 Percent Identity: 47.059

BASE COUNT 15 a /db\_xref="taxon:32630" 2 t  
ORIGIN

alignment\_scores:  
 Quality: 41.00 Length: 17  
 Percent Similarity: 76.471 Gaps: 0  
 Percent Identity: 47.059

alignment\_block:  
 US-09-439-311-2 x A12596/rev

Align seq 1/1 to reverse of: A12596 from: 1 to: 51

300 GlyArgGlyIleLysIleThrGlySerIleGlyValGlyAlaGlyIle 316  
 1 ||||| :::::|||||:::|||||:::|||||:::|||||:::|||||:::  
 51 GGGATCGGGTGGCTGGGTTGGGTGGCTGGGATCT 2

seq\_name: gb\_pat:A12597

seq\_documentation\_block:  
 LOCUS A12597 51 bp DNA PAT 05-JAN-1994  
 DEFINITION oligonucleotide.  
 ACCESSION A12597  
 VERSION A12597..1 GI:489543  
 KEYWORDS synthetic construct.

SOURCE synthetic construct.  
 AUTHORS artificial sequence.  
 REFERENCE 1 (bases 1 to 51)  
 JOURNAL Patent: WO 8701386-A 13 12-MAR-1987;  
 FEATURES Location/Qualifiers 1..51  
 source /organism="synthetic construct"

BASE COUNT 2 a /db\_xref="taxon:32630" 15 t  
ORIGIN

alignment\_scores:  
 Quality: 41.00 Length: 17  
 Percent Similarity: 76.471 Gaps: 0  
 Percent Identity: 47.059

alignment\_block:  
 US-09-439-311-2 x A12597

Align seq 1/1 to: A12597 from: 1 to: 51

300 GlyArgGlyIleLysIleThrGlySerIleGlyValGlyAlaGlyIle 316  
 1 ||||| :::::|||||:::|||||:::|||||:::|||||:::|||||:::  
 50 GGGATCGGGTGGCTGGGTTGGGTGGCTGGGATCT 50

316 u 316  
 1  
 51 C 51

seq\_name: gb\_pat:AX011428

seq\_documentation\_block:  
 LOCUS AR125926 60 bp DNA PAT 16-MAY-2001  
 DEFINITION Sequence 268 from patent: US 6177557.  
 ACCESSION AR125926  
 VERSION AR125926..1 GI:14111988  
 KEYWORDS  
 SOURCE Unknown.

ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 60)  
 AUTHORS Jaric,N., Gold,L. and Tasset,D.  
 TITLE High affinity ligands of basic fibroblast growth factor and thrombin

JOURNAL Patent: US 6177557-A 268 23-JAN-2001;  
 FEATURES Location/Qualifiers 1..60  
 source /organism="unknown"

BASE COUNT 10 a /db\_xref="taxon:32630" 11 c 29 g 10 t  
ORIGIN

alignment\_scores:  
 Quality: 40.00 Length: 19  
 Percent Similarity: 78.947 Gaps: 0  
 Percent Identity: 42.105

alignment\_block:  
 US-09-439-311-2 x AR125926

Align seq 1/1 to: AR125926 from: 1 to: 60

204 ThrSerValGlyThrGlyLeuGlyAlaLeuAlaGluLeuLeasnRgAs 220  
 4 ACCGCAGGGCGTAGCGGTGGAGGGTTGCCGATGGTAGGACAGGA 53  
 220 nalaAsp 222  
 ::::|||  
 54 CTCGGAT 60

SOURCE synthetic construct.

seq\_name: gb\_pat:124293  
 seq\_documentation\_block:  
 LOCUS 124293 60 bp DNA  
 DEFINITION Sequence 80 from patent US 5543293.  
 ACCESSION I24293  
 VERSION 124293.1 GI:1604163  
 KEYWORDS Unknown.  
 SOURCE Unclassified.  
 REFERENCE 1 (bases 1 to 60)  
 AUTHORS Gold,L. and Tasset,D.  
 TITLE DNA ligands of thrombin  
 JOURNAL Patent: US 5543293-A 80 06-AUG-1996;  
 FEATURES source 1..60  
 /organism="unknown"  
 BASE COUNT 10 a 11 c 29 g 10 t  
 ORIGIN

alignment\_scores:  
 Quality: 40.00 Length: 19  
 Ratio: 2.667 Gaps: 0  
 Percent Similarity: 78.947 Percent Identity: 42.105

alignment\_block:  
 Align seg 1/1 to: 124293 from: 1 to: 60

```

  204 ThrSerValGlyLysGlyLeuGlyAlaLeuAlaGluGluLeAspArgAsp 220
  ||||:|||:|||||||:|||||||:|||||||:|||||||:|||||||:|||:|||:|||:
  4 ACCGGGGAGGCCGTAGGGTGGAGCCGTGGCGATGTTAGSCACGGA 53
  220 nALaAsp 222
  ::::|||:||| 54 CTCGGAT 60

```

seq\_name: gb\_pat:AR013897  
 seq\_documentation\_block:  
 LOCUS AR013897 47 bp DNA  
 DEFINITION Sequence 97 from patent US 5773218.  
 ACCESSION AR013897  
 VERSION AR013897.1 GI:3971351  
 KEYWORDS SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 47)  
 AUTHORS Gallatin,W.Michael and Vazeux,R.  
 TITLE Method to identify compounds which modulate ICAM-related protein  
 interactions  
 JOURNAL Patent: US 5773218-A 97 30-JUN-1998;  
 FEATURES source 1..47  
 /organism="unknown"  
 BASE COUNT 9 a 21 c 7 g 10 t  
 ORIGIN

alignment\_scores:  
 Quality: 39.00 Length: 12  
 Ratio: 3.900 Gaps: 0  
 Percent Similarity: 83.333 Percent Identity: 66.667

alignment\_block:  
 US 09-439-311-2 x AR013897/rev ..

Align seg 1/1 to reverse of: AR013897 from: 1 to: 47

---

169 ArgPheGluThrGlySerGlnSerGlnSerGly 180
 |||:|||||:|||||:|||||:|||:|||||:|||:|||||:|||:|||||:|||:|||:  
 44 AGGATGGAGCTGGTCAGCAGATTGGAGTGG 9

seq\_name: gb\_pat:AR033851  
 seq\_documentation\_block:  
 LOCUS AR033851 47 bp DNA  
 DEFINITION Sequence 97 from patent US 5869262.  
 ACCESSION AR033851  
 VERSION AR033851.1 GI:5949456  
 KEYWORDS SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 47)  
 AUTHORS Gallatin,W.Michael and Vazeux,R.  
 TITLE Method for monitoring an inflammatory disease state by detecting  
 circulating ICAM-R  
 JOURNAL Patent: US 5869262-A 97 09-FEB-1999;  
 FEATURES source 1..47  
 /organism="unknown"  
 BASE COUNT 9 a 21 c 7 g 10 t  
 ORIGIN

alignment\_scores:  
 Quality: 39.00 Length: 12  
 Ratio: 3.900 Gaps: 0  
 Percent Similarity: 83.333 Percent Identity: 66.667

alignment\_block:  
 US 09-439-311-2 x AR042511/rev ..

Align seg 1/1 to reverse of: AR042511 from: 1 to: 47

---

169 ArgPheGluThrGlySerGlnSerGlnSerGly 180
 |||:|||||:|||||:|||||:|||:|||||:|||:|||||:|||:|||||:|||:|||:  
 44 AGGATGGAGCTGGTCAGCAGATTGGAGTGG 9

seq\_name: gb\_pat:AR042511  
 seq\_documentation\_block:  
 LOCUS AR042511 47 bp DNA  
 DEFINITION Sequence 97 from patent US 5811517.  
 ACCESSION AR042511  
 VERSION AR042511.1 GI:5063007  
 KEYWORDS SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 47)  
 AUTHORS Gallatin,W.Michael and Vazeux,R.  
 TITLE ICAM-related protein variants  
 JOURNAL Patent: US 5811517-A 97 22-SEP-1998;  
 FEATURES source 1..47  
 /organism="unknown"  
 BASE COUNT 9 a 21 c 7 g 10 t  
 ORIGIN

alignment\_scores:  
 Quality: 39.00 Length: 12  
 Ratio: 3.900 Gaps: 0  
 Percent Similarity: 83.333 Percent Identity: 66.667

alignment\_block:  
 US 09-439-311-2 x AR042511/rev ..

Align seg 1/1 to reverse of: AR042511 from: 1 to: 47

169 ArgPheGluThrGlySerClnSerPheSerSerGly 180  
 |||::||||||| ||||| |||:|||||  
 44 AGGATGGAGACTGGTCAGCACCATTTGGACTGGA 9

seq\_name: gb\_pat:AR058391

seq\_documentation\_block:

LOCUS AR058391 47 bp DNA

DEFINITION Sequence 97 from patent US 5837822.

ACCESSION AR058391

VERSION AR058391.1 GI:5983968

KEYWORDS

Unknown.

ORGANISM

Unclassified.

REFERENCE 1 (bases 1 to 47)

AUTHORS Gallatin,W Michael and Vazeux,R.

JOURNAL Patent: US 5837822-A 97-17-NOV-1998;

FEATURES Location/Qualifiers

source

1..47

BASE COUNT 9 a /organism="unknown"

21 c 7 g 10 t

ORIGIN

alignment\_scores:

Quality: 39.00

Length:

12

Ratio: 3.900

Gaps: 0

Percent Similarity: 83.333

Percent Identity: 66.667

alignment\_block:

US-09-439-311-2 x AR058391/rev

Align seg 1/1 to reverse of: AR058391 from: 1 to: 47

169 ArgPheGluThrGlySerClnSerPheSerSerGly 180  
 |||::||||||| ||||| |||:|||||  
 44 AGGATGGAGACTGGTCAGCACCATTTGGACTGGA 9

seq\_name: gb\_pat:AR088217

seq\_documentation\_block:

LOCUS AR088217 47 bp DNA

PAT

07-SEP-2000

DEFINITION Sequence 97 from patent US 5989843.

ACCESSION AR088217

VERSION AR088217.1 GI:10014980

KEYWORDS

Unknown.

ORGANISM

Unclassified.

REFERENCE 1 (bases 1 to 47)

AUTHORS Gallatin,W Michael and Vazeux,R.

TITLE Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein

Patent: US 5989843-A 97-23-NOV-1999;

FEATURES Location/Qualifiers

source

1..47

BASE COUNT 9 a /organism="unknown"

21 c 7 g 10 t

ORIGIN

alignment\_scores:

Quality: 39.00

Length: 12

Gaps: 0

Percent Similarity: 83.333

Percent Identity: 66.667

alignment\_block:

US-09-439-311-2 x AR088217/rev

Align seg 1/1 to reverse of: AR088217 from: 1 to: 47

169 ArgPheGluThrGlySerClnSerPheSerSerGly 180  
 |||::||||||| ||||| |||:|||||  
 44 AGGATGGAGACTGGTCAGCACCATTTGGACTGGA 9

Wed Apr 17 07:36:47 2002

us-09-439-311-2.rge

Gencore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

On nucleic - nucleic search, using sw model  
Run on: April 16, 2002, 23:26:24 ; Search time 1531.8 Seconds  
(without alignments)  
10759.030 Million cell updates/sec

Title: US-09-439-311-1

Perfect score: 999  
Sequence: 1 attaacacaatgtgcagc.....ttaaaaatgtatggtagagat 999

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 1472140 seqs, 8248589755 residues

Total number of hits satisfying chosen parameters: 586436

Minimum DB seq length: 0

Maximum DB seq length: 60

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

1: GenEmpl:\*  
2: gb\_ba:/\*  
3: gb\_htg:/\*  
4: gb\_in:/\*  
4: gb\_om:/\*  
5: gb\_ov:/\*  
6: gb\_pat:/\*  
7: gb\_ph:/\*  
8: gb\_pl:/\*  
9: gb\_pr:/\*  
10: gb\_ro:/\*  
11: gb\_sts:/\*  
12: gb\_sy:/\*  
13: gb\_vl:/\*  
14: gb\_vl:/\*  
15: em\_ba:/\*  
16: em\_fun:/\*  
17: em\_hum:/\*  
18: em\_in:/\*  
19: em\_om:/\*  
20: em\_or:/\*  
21: em\_ov:/\*  
22: em\_pat:/\*  
23: em\_ph:/\*  
24: em\_pl:/\*  
25: em\_ro:/\*  
26: em\_sts:/\*  
27: em\_sy:/\*  
28: em\_un:/\*  
29: em\_vl:/\*  
30: em\_htgo\_hum:/\*  
31: em\_htgo\_inv:/\*  
32: em\_htgo\_rnd:/\*  
33: em\_htg\_hum:/\*  
34: em\_htg\_inv:/\*  
35: em\_htg\_rnd:/\*  
36: em\_htg\_other:/\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

RESULT	Score	Query	Length	DB	ID	Description
AR153100/C	1	c	1	26.8	2.7	30 AR153100 Sequence
LOCUS		AR153100	30 bp	DNA		AR153101 Sequence
DEFINITION			Sequence 102 from patent US 6235480.			
ACCESSION		AR153100				AR001228 Sequence
VERSION		AR153100.1	GI:15120632			AR008251 Sequence
KEYWORDS						AR054102 Sequence
SOURCE		Unknown.				AX052949 Sequence 6
ORGANISM		Unclassified.				AR052949 Sequence 6
UNP						AR052949 Sequence 6
ALIGNMENTS						
TITLE		1 (bases 1 to 30), Shultz,J.William, Lewis,M.K., Leippe,D., Mandrekar,M., Kephart,D., Olson,R.J., Wood,K.V. and Welch,R.		PAT		
JOURNAL		Rhodes,R.Byron, Andrews,C.Ann, Hartnett,J.Robert, Gu,T.,				
FEATURES		Patent: US 6235480-A 102-22-MAY-2001; Location/Qualifiers				
SOURCE		1. 3D /organism="unknown"				
BASE COUNT	5 a	5 c	4 g	16 t		

## ORIGIN

Query Match 2.7%; Score 26.8; DB 6; Length 30;  
 Best Local Similarity 93.3%; Pred. No. 1.4e+05; 0; Mismatches  
 Matches 28; Conservative 0; Indels 0; Gaps 0;

repeat\_region  
 ORIGIN Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 30)

AUTHORS Shultz, J., William, Lewis, M. K., Leippe, D., Mandrekar, M., Kephart, D.,  
 Rhodes, R., Byron, Andrews, C., Ann, Hartnett, J., Robert, Gu, T.,  
 Olson, R. J., Wood, K. V., and Welch, R.

TITLE Detection of nucleic acid hybrids

JOURNAL Patent: US 6235480-A 103 22-MAY-2001;

FEATURES source 1..30 Location/Qualifiers

RESULT 2

ARL53101 ARL53101 30 bp DNA PAT 08-AUG-2001

LOCUS Sequence 103 from patent US 6235480.

DEFINITION ARI53101 AR153101.1. GI:15120633

ACCESSION VERSION

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 30)

AUTHORS Shultz, J., William, Lewis, M. K., Leippe, D., Mandrekar, M., Kephart, D.,  
 Rhodes, R., Byron, Andrews, C., Ann, Hartnett, J., Robert, Gu, T.,  
 Olson, R. J., Wood, K. V., and Welch, R.

TITLE Detection of nucleic acid hybrids

JOURNAL Patent: US 6235480-A 103 22-MAY-2001;

FEATURES source 1..30 Location/Qualifiers

BASE COUNT 16 a 4 c 5 g 5 t

RESULT 3

AF220167 AF220167 60 bp DNA INN 23-APR-2001

DEFINITION Drosophila pseudoobscura strain Abajo36 bicoid (bcd) gene, partial  
 cds.

ACCESSION ARF320167

VERSION AR320167.1 GI:13752322

KEYWORDS

SOURCE Drosophila pseudoobscura.

ORGANISM Drosophila pseudoobscura

Pterygota; Metazoa; Arthropoda; Tracheata; Hexapoda; Brachycera;  
 Muscomorpha; Ephydriodea; Drosophilidae; Drosophila.

REFERENCE 1 (bases 1 to 60)

AUTHORS Moor, M. A., Kliman, R. M. and MacCabe, C. A.

TITLE Evolutionary history of microsatellites in the obscura group of  
 Drosophila

JOURNAL Mol. Biol. Evol. 18 (4), 551-556 (2001)

MEDLINE 2116527

PUBMED 11264406

REFERENCE 2 (bases 1 to 60)

AUTHORS Moor, M. A. F., Kliman, R. M. and Machado, C. A.

TITLE Direct submission (08-NOV-2000) Genetics, Rutgers University, 604 Allison  
 Rd., Piscataway, NJ 08854, USA

JOURNAL Submitted (Location/Qualifiers 1..60)

FEATURES source /organism="Drosophila pseudoobscura"

gene  
 /db\_xref="taxon:7237"  
 <1..>60  
 /gene="bcd"  
 exon  
 <1..>60  
 /rpt\_type=tandem  
 /gene="bcd"  
 /number=3  
 repeat\_region  
 /note="microsatellite"  
 /codon\_start=1  
 /product="bcd"  
 /protein\_id="ANR38619\_1"  
 /db\_xref="GI:13752323"  
 /translation="XQPFQTOQQQOLHQQQQQ"  
 CDS  
 BASE COUNT 21 a 19 c 12 g 7 t 1 others

RESULT 4

AR001228/c AR001228 24 bp DNA PAT 04-DEC-1998

LOCUS AR001228 Sequence 6 from patent US 5738995.

DEFINITION AR001228

ACCESSION AR001228.1 GI:3963295

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 24)

AUTHORS Wu, L., Coombs, J., Malmstrom, S. L. and Glass, M. J.

TITLE Inosine-containing probes for detecting E. coli

JOURNAL Patent: US 5738995-A 6 14-APR-1998;

FEATURES source Location/Qualifiers

BASE COUNT 6 a 5 c 5 g 8 t

RESULT 5

AR008251/c AR008251 24 bp DNA PAT 04-DEC-1998

LOCUS AR008251 Sequence 6 from patent US 5735444.

DEFINITION AR008251

ACCESSION AR008251

VERSION AR008251.1 GI:3967360

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 24)

AUTHORS Wu, L., Coombs, J., Malmstrom, S. L. and Glass, M. J.

TITLE Methods and kits using inosine-containing probes for discriminating  
 variant nucleic acid sequences



LOCUS	AR061278	PAT	29-SEP-1999
DEFINITION	Sequence 7 from Patent US 5843650.		
ACCESSION	AR061278		
VERSION	AR061278.1	GI:5988969	
KEYWORDS	Unknown.		
ORGANISM	Unclassified. 1 (bases 1 to 58)		
REFERENCE	Segev,D.		
AUTHORS	Nucleic acid detection and amplification by chemical linkage of oligonucleotides		
TITLE	Patent: US 5843650-A 7 01-DEC-1998: 1..58 Location/Qualifiers		
JOURNAL	Patent: WO 0140521-A 3821 07-JUN-2001;		
SOURCE	Curagen Corporation (US) Location/Qualifiers		
FEATURES	source		
BASE COUNT	15 a 18 c 13 g 12 t		
ORIGIN			
RESULT	11		
LOCUS	A80405	DNA	
DEFINITION	Sequence 17 from Patent WO951771.		
ACCESSION	A80405	PAT	
VERSION	1 GI:6731293		
KEYWORDS	Archaeoglobus fulgidus.		
SOURCE	Archaeoglobus fulgidus Archaea; Euryarchaeota; Archaeoglobales; Archaeoglobaceae;		
ORGANISM			
REFERENCE	1 (bases 1 to 60)		
AUTHORS	Jansen, R. and Schouls,L.M.		
TITLE	A METHOD OF INVERSTRAIN DIFFERENTIATION OF BACTERIA JOURNAL		
PATENT	WO 951771-A 17 14-OCH-1995; JANSSEN RUDOLPH (NL)		
EMBDED	JOHANNES DIRK ANTHONIE (NL); JANSSEN RUDOLPH (NL)		
FEATURES	Location/Qualifiers		
SOURCE	1..60 /organism="Archaeoglobus fulgidus" 'ab_xref="taxon:2234"		
BASE COUNT	20 a 11 c 9 g 20 t		
ORIGIN			
RESULT	12		
LOCUS	AX160493	DNA	
DEFINITION	Sequence 3821 from Patent WO0140521.		
ACCESSION	AX160493	PAT	
VERSION	AX160493.1	GI:14541824	
KEYWORDS	human.		
SOURCE	Homo sapiens		
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Buterilia; Primates; Catarrhini; Hominidae; Homo.		
RESULT	13		
LOCUS	AX160494	DNA	
DEFINITION	Sequence 3822 from Patent WO0140521.		
ACCESSION	AX160494	PAT	
VERSION	AX160494.1 GI:14541825		
KEYWORDS	human.		
SOURCE	Homo sapiens		
ORGANISM			
REFERENCE	1 (bases 1 to 51)		
AUTHORS	Shimkets,R.A. and Leach,M.		
TITLE	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof		
JOURNAL	Curagen Corporation (US)		
PATENT	WO 0140521-A 3822 07-JUN-2001;		
EMBDED	1..51 Location/Qualifiers		
FEATURES	misc_feature		
SOURCE	/organism="Homo sapiens" 'ab_xref="taxon:9606"		
BASE COUNT	18 a 5 c 8 g 20 t		
ORIGIN			
RESULT	14		
LOCUS	AF220169	DNA	
DEFINITION	AF320169 Drosophila pseudoobscura strain Mather10 bicoid (bcd) gene, partial cds.		
ACCESSION	AF320169	INV	
VERSION	AF320169.1 GI:13752326		
KEYWORDS	Drosophila pseudoobscura.		
SOURCE	Drosophila pseudoobscura		
ORGANISM			



Wed Apr 17 07:36:44 2002

us-09-439-311-1.rge

GenCore version 4.5  
 Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 17, 2002, 01:18:44 ; Search time 172.86 Seconds  
 (without alignments)  
 4954.691 Million cell updates/sec

Title: US-09-439-311-1

Perfect score: 999

Sequence: 1 attacacacaatgttgcagc.....taaaaaatgtatgttagat 999

Scoring table: IDENTITY\_NUC

Gapop 10.0 , Gapext 1.0

Searched: 930621 seqs, 428662619 residues

Total number of hits satisfying chosen parameters: 1026190

Minimum DB seq length: 0

Maximum DB seq length: 60

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : N\_Geneseq\_1101:\*

1: /SIDS2/gcgdata/geneseq/geneseq/geneseq/NA1980.DAT:\*

2: /SIDS2/gcgdata/geneseq/geneseq/geneseq/NA1981.DAT:\*

3: /SIDS2/gcgdata/geneseq/geneseq/geneseq/NA1982.DAT:\*

4: /SIDS2/gcgdata/geneseq/geneseq/geneseq/NA1983.DAT:\*

5: /SIDS2/gcgdata/geneseq/geneseq/geneseq/NA1984.DAT:\*

6: /SIDS2/gcgdata/geneseq/geneseq/NA1985.DAT:\*

7: /SIDS2/gcgdata/geneseq/geneseq/NA1986.DAT:\*

8: /SIDS2/gcgdata/geneseq/geneseq/NA1987.DAT:\*

9: /SIDS2/gcgdata/geneseq/geneseq/NA1988.DAT:\*

10: /SIDS2/gcgdata/geneseq/geneseq/NA1989.DAT:\*

11: /SIDS2/gcgdata/geneseq/geneseq/NA1990.DAT:\*

12: /SIDS2/gcgdata/geneseq/geneseq/NA1991.DAT:\*

13: /SIDS2/gcgdata/geneseq/geneseq/NA1992.DAT:\*

14: /SIDS2/gcgdata/geneseq/geneseq/NA1993.DAT:\*

15: /SIDS2/gcgdata/geneseq/geneseq/NA1994.DAT:\*

16: /SIDS2/gcgdata/geneseq/geneseq/NA1995.DAT:\*

17: /SIDS2/gcgdata/geneseq/geneseq/NA1996.DAT:\*

18: /SIDS2/gcgdata/geneseq/geneseq/NA1997.DAT:\*

19: /SIDS2/gcgdata/geneseq/geneseq/NA1998.DAT:\*

20: /SIDS2/gcgdata/geneseq/geneseq/NA1999.DAT:\*

21: /SIDS2/gcgdata/geneseq/geneseq/NA2000.DAT:\*

22: /SIDS2/gcgdata/geneseq/geneseq/NA2001.DAT:\*

**Pred.** No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query	Length	DB ID	Description
c 1	25.8	2.7	30	21 AAX86891	Probe to Campylobacter jejuni
c 2	26.8	2.7	30	21 AAX86892	Probe to Campylobacter jejuni
c 3	26.8	2.7	30	21 AAX93190	Campylobacter jejuni
c 4	26.8	2.7	30	21 AAX93190	Campylobacter jejuni
c 5	21.8	2.2	50	20 AAX52169	Synthetic plasmid
c 6	21.4	2.1	51	19 AAV04223	Human cardiac tropomyosin
c 7	21.4	2.1	59	19 AAV04224	Human cardiac tropomyosin
c 8	21.2	2.1	54	21 AAV97417	Pea wild-type pRb
c 9	21.2	2.1	27	21 AAV27148	Campylobacter coli
c 10	21	2.1	33	21 AAV27149	Campylobacter coli
c 11	20.8	2.1	24	18 AAI60503	Primer CFO4R.4.

## ALIGNMENTS

RESULT 1	AA86891/C	ID AA86891 standard; DNA; 30 BP.
XX	AC	AA86891;
XX	XX	15-JAN-2001 (first entry)
DT	XX	DE Probe to <i>Campylobacter jejuni</i> .
XX	XX	XX Detection; nucleic acid hybridization; depolymerisation; analysis; SNP; single nucleotide polymorphism; identification; viral load; probe; genotyping; medical marker diagnostic; primer; target; mutation; genetic disease; ss.
KW	KW	KW
XX	OS	Campylobacter jejuni.
XX	PN	WO200049180-A1.
XX	PD	24-AUG-2000.
XX	PP	18-FEB-2000; 2000WO-US04242.
XX	PR	18-FEB-1999; 990US-0252436.
PR	PR	21-JUL-1999; 990US-0358972.
PR	XX	25-AUG-1999; 99US-0383316.
PA	PA	(PROM-) PROMEGA CORP.
PA	PI	Shultz JW, Lewis MK, Leippe D, Mandrekar M, Kephart D, Rhodes RB; Andrews CA, Hartnett JR, Gu T, Olson RJ, Wood KV, Welch R;
PT	XX	WPI; 2000-565377/52.

PT Determining presence or absence of a predetermined endogenous nucleic acid sequence by using an enzyme that depolymerizes the 3' end of an oligonucleotide probe hybridized to a target sequence to release identifier nucleotides -

XX Example; Page 321; 389pp; English.

CC The present invention describes a method (M1) for determining the presence or absence of a predetermined endogenous nucleic acid target sequence (ENAT). The method comprises hybridising a probe having an identifier nucleotide (IN) with ENAT which is treated with an enzyme that depolymerises the 3' end of hybridised NA to release the INs. M1 is used for determining the number of known sequence repeats present in a nucleic acid target sequence in a nucleic acid sample. The method is also useful for determining whether a nucleic acid target sequence in a sample is an allele from a homozygous or heterozygous locus. The method is also useful for detection of mutations, translocations and SNPs in nucleic acids (including those associated with genetic disease), contamination, and analysis of forensic samples. AA86791 to AAB12817 represent sequence which are used in the exemplification of the present invention.

CC N.B. There is a discrepancy between the SEQ ID NO: and sequences given in the examples, and the SEQ ID NO: and sequences given in the sequence listing from the present invention.

CC Sequence 30 BP; 5 A; 5 C; 4 G; 16 T; 0 other;

CC Query Match 2.7%; Score 26.8; DB 21; Length 30; Best Local Similarity 93.3%; Pred. No. 1.3e+03; Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 289 caagatgttcaaggcttaaaaaaagaact 318

Db 30 CAAGATGGACAAGTTAAACAAAGACT 1

RESULT 2

ID AA86892

ID AAA86892 standard; DNA; 30 BP.

XX AC AA86892;

XX DT 15-JAN-2001 (first entry)

XX DE Probe to *Campylobacter jejuni*.

XX KW Detection; nucleic acid hybrid; depolymerisation; analysis; SNP; single nucleotide polymorphism; identification; viral load; probe; genotyping; medical marker diagnostic; primer; target; mutation; genetic disease; ss.

XX OS *Campylobacter jejuni*.

XX PN WO200049180-A1.

XX PD 24-AUG-2000.

XX PF 18-FEB-2000; 2000WO-US04242.

XX PR 18-FEB-1999; 99US-0252436.

XX PR 21-JUL-1999; 99US-0358972.

XX PR 25-AUG-1999; 99US-0383316.

XX PA (PROM-) PROMEGA CORP.

XX PI Shultz JW, Lewis MK, Leippe D, Mandrekar M, Kephart D, Rhodes RB; Andrews CA, Hartnett JR, Gu T, Olson RJ, Wood KV, Welch R;

XX DR WPI; 2000-565377/52.

PT Determining presence or absence of a predetermined endogenous nucleic acid sequence by using an enzyme that depolymerizes the 3' end of an oligonucleotide probe hybridized to a target sequence to release identifier nucleotides

XX Example; Page 321; 389pp; English.

CC The present invention describes a method (M1) for determining the presence or absence of a predetermined endogenous nucleic acid target sequence (ENAT). The method comprises hybridising a probe having an identifier nucleotide (IN) with ENAT which is treated with an enzyme that depolymerises the 3' end of hybridised NA to release the INs. M1 is used for determining the number of known sequence repeats present in a nucleic acid target sequence in a nucleic acid sample. The method is also useful for determining whether a nucleic acid target sequence in a sample is an allele from a homozygous or heterozygous locus. The method is also useful for detection of mutations, translocations and SNPs in nucleic acids (including those associated with genetic disease), determination of viral load, species identification, sample contamination, and analysis of forensic samples. AA86791 to AAB12817 represent sequence which are used in the exemplification of the present invention.

CC N.B. There is a discrepancy between the SEQ ID NO: and sequences given in the examples, and the SEQ ID NO: and sequences given in the sequence listing from the present invention.

CC Sequence 30 BP; 16 A; 4 C; 5 G; 5 T; 0 other;

CC Query Match 2.7%; Score 26.8; DB 21; Length 30; Best Local Similarity 93.3%; Pred. No. 1.3e+03; Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 289 caagatgttcaaggcttaaaaaaagaact 318

Db 1 caagatggacaaaggttaaaaacaagaact 30

RESULT 3

ID AA93188/C

ID AAA93188 standard; DNA; 30 BP.

XX AC AAA93188;

XX DT 11-JAN-2001 (first entry)

XX DE *Campylobacter jejuni* interrogation probe 11451.

XX KW *Campylobacter jejuni*; nucleic acid detection; genomic typing; mutation detection; viral load determination; species identification; forensic analysis; probe; ss.

XX OS *Campylobacter jejuni*.

XX PN WO200049179-A1.

XX PD 24-AUG-2000.

XX PF 18-FEB-2000; 2000WO-US04176.

XX PR 18-FEB-1999; 99US-0252436.

XX PR 21-JUL-1999; 99US-0358972.

XX PR 27-SEP-1999; 99US-0406147.

XX PA (PROM-) PROMEGA CORP.

XX PI Shultz JW, Lewis MK, Leippe D, Mandrekar M, Kephart D, Rhodes RB; Andrews CA, Hartnett JR, Gu T, Olson RJ, Wood KV, Welch R;

XX DR WPI; 2000-549282/50.

PT Detecting the presence of predetermined exogenous nucleic acid target sequence useful for e.g. genotyping, comprises depolymerizing the 3' end of an oligonucleotide probe hybridized to a nucleic acid target

PT sequence .  
 XX  
 RS Claim 47; Page 187; 230pp; English.  
 XX  
 CC The present sequence is an interrogation probe which was used to detect a segment of the genome of *Campylobacter jejuni*. This was performed as part of a method for determining the presence of a known exogenous nucleic acid target sequence in a nucleic acid sample. The method comprises adding a treated sample with a depolymerising enzyme which releases one or more nucleotides from the 3'-end of a hybridised nucleic acid probe. The method is used for assaying nucleic acids for a particular native or mutant sequence, and for genomic typing. It is useful for detecting mutations, translocations, and single nucleotide polymorphisms, determination of viral load, species identification, detection of sample contamination, and analysis of forensic samples. Compared with previous methods of detecting nucleic acid hybrids, the new method has higher sensitivity without the need for radiochemicals or electrophoresis. It is quantitatively, highly reproducible and can be automated. The method can reliably detect as few as 10 copies of a virus in a sample, and is capable of providing multiple analyses in a single assay (multiplex assay).  
 XX  
 Sequence 30 BP; 5 A; 5 C; 4 G; 16 T; 0 other;

Query Match

Score 25.8; DB 21; Length 30;

Best Local Similarity 93.3%; Pred. No. 1.3e+03; Mismatches 0; Indels 0; Gaps 0;

QY

289 caagatggtaaaacaaagaact 318

Db 30 CAGATGGACAAAGTTAAAACAAAGACT 1

RESULT 4

ID AAA93190 standard; DNA; 30 BP.

XX

AC AAA93190;

XX

DT 11-JAN-2001 (first entry)

XX

DE *Campylobacter jejuni* interrogation probe 11450.

XX

KW Campylobacter *jejuni*; nucleic acid detection; genomic typing; mutation detection; viral load determination; species identification; forensic analysis; probe; ss.

XX

OS *Campylobacter jejuni*.

XX

PN WO200049179-A1.

XX

PD 24-AUG-2000.

XX

PF 18-FEB-2000; 2000WO-US04176.

XX

PR 18-FEB-1999; 99US-0252436.

XX

PR 21-JUL-1999; 99US-0358972.

XX

PR 27-SEP-1999; 99US-0406147.

XX

PA (PROM-) PROMEGA CORP.

XX

PT Shultz JW, Lewis MK, Leippe D, Mandrekar M, Kephart D, Rhodes RB;

PI Andrews CA, Hartnett JR, Gu T, Olson RJ, Wood KV, Welch R;

XX

DR WPI; 2000-549282/50.

XX

PT Detecting the presence of predetermined exogenous nucleic acid target sequence useful for e.g. genotyping, comprises depolymerizing the 3' end of an oligonucleotide probe hybridized to a nucleic acid target

PT sequence .  
 XX  
 PS Claim 47; Page 187; 230pp; English.

XX  
 CC The present sequence is an interrogation probe which was used to detect a segment of the genome of *Campylobacter jejuni*. This was performed as part of a method for determining the presence of a known exogenous nucleic acid target sequence in a nucleic acid sample. The method comprises adding a treated sample with a depolymerising enzyme which releases one or more nucleotides from the 3'-end of a hybridised nucleic acid probe. The method is used for assaying nucleic acids for a particular native or mutant sequence, and for genomic typing. It is useful for detecting mutations, translocations, and single nucleotide polymorphisms. The determination of viral load, species identification, detection of sample contamination, and analysis of forensic samples. Compared with previous methods of detecting nucleic acid hybrids, the new method has higher sensitivity without the need for radiochemicals or electrophoresis. It is quantitatively, highly reproducible and can be automated. The method can reliably detect as few as 10 copies of a virus in a sample, and is capable of providing multiple analyses in a single assay (multiplex assay).  
 XX  
 Sequence 30 BP; 16 A; 4 C; 5 G; 5 T; 0 other;

Query Match

Score 26.8; DB 21;

Length 30;

Best Local Similarity 93.3%; Pred. No. 1.3e+03; Mismatches 0; Indels 0; Gaps 0;

Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY

289 caagatggtaaaacaaagaact 318

Db 1 caagatggtaaaacaaagaact 30

RESULT 5

ID AAX2169/C

XX

AC AAX2169;

XX

DT 18-JUN-1999 (first entry)

XX

DE Synthetic plasmid synlux4 construction oligonucleotide R53.

XX

KW DNA Plasmid; lux A; lux B; *Vibrio fisheri*; luciferase; promoter;

KW tng kanamycin/neomycin phosphotransferase; DNA synthesis;

KW replication competent double-stranded polynucleotide; ss.

OS Synthetic.

XX

PN WO9914318-A1.

XX

PD 25-MAR-1999.

XX

PF 16-SEP-1998; 98WO-US19312.

XX

PR 16-SEP-1997; 97US-0059017.

XX

PA (TEXA ) UNIV TEXAS SYSTEM.

XX

PI Evans GA;

XX

DR WPI; 1999-244029/20.

XX

PT Synthesis of replication competent double-stranded polynucleotides

XX

PS Example 4; Fig 5E; 135pp; English.

XX

CC AAX2021-212 represent oligonucleotide primers that were used to construct a synthetic DNA plasmid sequence synlux4, to demonstrate the method of the invention. Within the synlux4 sequence are included the sequences of lux A, lux B, the A and B components of the *Vibrio fisheri* luciferase sequence, positions of pUC19 including the origin of replication and replication stability sequences, and the promoter and coding sequence for tng kanamycin/neomycin phosphotransferase. The specification describes a method for the synthesis of replication

CC

Page  
4

CC CC competent double-stranded polynucleotides. The method comprises generating a first set of oligonucleotides corresponding to the plus strand and a second set corresponding to the minus strand and annealing. The method can be used for preparing polynucleotides containing sequences involved in a biochemical pathway. In particular, they can be used to produce polynucleotides encoding enzymes, e.g. hexokinase, phosphoenolpyruvate isomerase, phosphofructokinase-1, aldolase, triose-phosphate isomerase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, phosphoglycerate mutase, enolase or pyruvate kinase. They can also be used for the preparation of viral particles, artificial genomes and artificial genetic systems.

Query	Match	Score	DB	Length
Best Local	Similarity		20;	50;
Matches	29;	Conservative:	Pred. NO.	Mismatches
Qy	ttaatttcagctatcaatgtcgtaaaagataacaacttgggt	848	21.8;	2.2%
Db	TCAATGTCGGATTAAGATGTTAAGTATTTGATAT	3	2.3e+04;	0;

AAV04224/C  
 ID AAV04224 standard; DNA; 58 BP.  
 XX  
 AC . AAV04224;  
 XX  
 DT 22-JUN-1998 (first entry)  
 XX  
 DE Human cardiac troponin C 5' PCR primer.  
 XX

DE Human cardiac troponin I/troponin C 3' PCR primer.  
 XX  
 KW Troponin I; troponin C; immunoassay; assay; analysis; human;  
 KW cardiac muscle; skeletal muscle; injury; myocardial infarction;  
 KW diagnosis; HcTnI; HcTnC; PCR; primer; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN WO9739132-A1.  
 XX  
 PD 23-OCT-1997.  
 XX  
 PF 14-APR-1997; 97WO-US06147.  
 XX  
 PR 11-APR-1997; 97US-0033743.  
 PR 16-APR-1996; 96US-0015772.  
 XX  
 PA (UWMI-) UNIV MIAMI.  
 XX  
 PI Potter JD;  
 XX  
 DR WPI: 1998-062676/06.  
 XX  
 PT Immunoassay of mammalian troponin using stable standard for  
 PT comparison - specifically acid-dialysed solution or its lyophilisate  
 used for diagnosis of cardiac or skeletal muscle damage  
 XX  
 PS Example 3; Page 34; 94BP; English.  
 XX  
 CC This 3' PCR primer was used in the amplification of human cardiac  
 CC troponin I (HcTnI) cDNA. It is a complementary sequence encoding  
 CC the C-terminal 8 amino acids of HcTnI followed by the N-terminal 8  
 CC amino acids of human cardiac troponin C (HcTnC). It was used with  
 CC a vector-based 5' primer in the PCR amplification of HcTnI plasmid  
 CC DNA. HcTnC DNA was also amplified (see AAV04223), and the PCR  
 CC products were used to construct a polynucleotide (see AAV04225)  
 CC encoding a HcTnI/HcTnC fusion protein (see AAW1571). The addition  
 CC of the calcium binding Protein HcTnC to HcTnI was made to provide  
 more favourable solubility properties. The fusion protein can be  
 used as a standard in novel assays of mammalian troponin.  
 CC

AAA97417  
 ID AAA97417 standard; DNA; 54 BP.  
 XX  
 AC  
 XX  
 DT 29-JAN-2001 (first entry)  
 XX Pea wild-type *pra2* gene light-repressible promoter oligonucleotide, WT3.  
 DE GMP-binding protein *pra2*; Pea; light-repressible promoter;  
 KW photoinhibitory; expression cassette; transgenic plant;  
 KW deterioration prevention; storage; ss.  
 XX Pisum sativum.  
 XX PN WO20035313-A1.  
 XX PD 21-SEP-2000.  
 XX PF 03-MAR-2000; 2000WO-JP01269.  
 XX PR 12-MAR-1999; 99JP-0066551.  
 XX PA (SUNR ) SUNTORY LTD.  
 XX PI Sasaki Y, Nagano Y, Inaba T;  
 XX DR WPI; 2000-587526/55.  
 XX PT New DNA fragment or promoter for expressing a target gene, specifically  
 under photoinhibitory conditions, and for transforming a plant cell or  
 plant to improve quality and prevent deterioration during storage  
 XX PS Example 9; Page 19; 49pp; Japanese.  
 CC The invention relates to a light-repressible promoter (AAA97385), or  
 active fragments thereof (AAA97383, AAA97384), from the gene encoding  
 the pea GMP-binding protein *pra2*. The invention also relates to an  
 expression cassette containing the *pra2* promoter or its active  
 fragments for the expression of a gene under photoinhibitory or dark  
 CC conditions in a plant, and to transgenic plants, their descendants  
 CC and plant tissues comprising the expression cassette. The expression  
 cassette of the invention can be used to generate transgenic plants in  
 CC which deterioration during storage in the dark is prevented. This is  
 particularly useful for agricultural products. Sequences AAA97417-97418  
 CC represent oligonucleotides used in an exemplification of the invention  
 to generate a wild-type pea *pra2* promoter fragment.  
 XX SQ Sequence 54 BP; 18 A; 3 C; 12 G; 21 T; 0 other;  
 CC Query Match 2.1%; Score 21.2; DB 21; Length 54;  
 CC Best Local Similarity 64.0%; Pred. No. 3.3e+04;  
 CC Matches 32; Conservative 0; Mismatches 18; Indels 0; Gaps 0;  
 CC QY 738 taggattttgtctatcaatgggttgttataatgttaatgttgttattcag 787  
 CC DB 1 taggatttttagttacaaatggatttacacataattggaggatttccag 50  
 CC OS Campylobacter coli.  
 XX PN WO200027205-A1.  
 XX PD 18-MAY-2000.  
 XX PF 12-NOV-1999; 99WO-US27195.  
 XX PR 12-NOV-1998; 98US-0108114.  
 XX PA (USAT ) US SEC.  
 XX PI Guerry P, Trust T, Burg E, Lee L;  
 XX DR WPI; 2000-37214/32.  
 OS Campylobacter coli.  
 XX PN WO200027205-A1.  
 XX PD 18-MAY-2000.  
 XX PF 12-NOV-1999; 99WO-US27195.  
 XX PR 12-NOV-1998; 98US-0108114.  
 XX PA (USAT ) US SEC.  
 XX PI Guerry P, Trust T, Burg E, Lee L;  
 XX DR WPI; 2000-37214/32.  
 OS Campylobacter coli.  
 XX PN WO200027205-A1.  
 XX PD 18-MAY-2000.  
 XX PF 12-NOV-1999; 99WO-US27195.  
 XX PR 12-NOV-1998; 98US-0108114.  
 XX PA (USAT ) US SEC.  
 XX PI Guerry P, Trust T, Burg E, Lee L;  
 XX DR WPI; 2000-37214/32.

PT Campylobacter FlaA protein and coding sequence, useful in reducing  
 PT Campylobacter intestinal colonization  
 XX disclosure; Page 7; 43pp; English.

CC The flaA gene encodes the major flagellin subunit of the Campylobacter  
 CC coil flagellar filament. Part of the FlaA polypeptide may be fused with  
 CC the maltose binding protein of *Escherichia coli* to make a recombinant  
 CC protein. When this protein is introduced into a host an immunological  
 CC response is triggered. Therefore the recombinant protein may be used as  
 CC a vaccine to protect against *C. coli* intestinal colonisation and the  
 CC diarrhoea it causes. This vaccine system is useful as it can  
 prevent the development of Guillain-Barre syndrome (GBS) which is seen  
 CC with whole cell Campylobacter vaccines. The present sequence is the  
 CC flaA-2 PCR primer that was used to amplify part of the flaA gene.  
 XX Sequence 33 BP; 10 A; 8 C; 1 G; 14 T; 0 other;

Query Match 2.1%; Score 21; DB 21; Length 33;  
 Best Local Similarity 100.0%; Pred. No. 3.3e+04; Indels 0; Gaps 0;  
 Matches 21; Conservative 0; Mismatches 0;

OY 979 gttaaaaatgtatggatagat 999  
 |||||||  
 33 GTTAAATGTATGGAGAT 13

Db

RESULT 11  
 ID AAT60508/C  
 ID AAT60508 standard; DNA; 24 BP.  
 AC AAT60508;  
 DT 10-JUN-1997 (first entry)  
 DE Primer CFO4R.4.  
 KW PCR; polymerase chain reaction; amplify; infection; forensic science;  
 KW infectious pathogen; genetic disorder; genetic variance; primer; ss.  
 OS Synthetic.  
 XX US5612473-A.  
 XX 18-MAR-1997.  
 XX 16-JAN-1996; 96US-0587209.  
 PR 16-JAN-1996; 96US-0587209.  
 PA (GULL-) GULL LAB.  
 XX  
 PT Coombs J, Glass MJ, Malmstrom SL, Wu L;  
 DR WPI; 1997-192163/17.

XX Processing samples for amplification of nucleic acid target  
 PT sequences - using extraction buffer containing at least one  
 PT detergent and a salt composition of greater than 1 molar  
 PT concentration  
 PS Example 3; Column 17; 21pp; English.

CC AMT60503-T60514 represent amplification primers for DNA sequences  
 CC present in a sample processed by the method of the invention. The  
 CC processing method of the invention comprises obtaining a sample of  
 CC material potentially containing the target nucleic acid sequences, and  
 CC mixing the sample with an external buffer solution. The buffer solution  
 CC comprises two detergents, and at least one salt composition present in a  
 CC greater than 1 M concentration. The mixture is then centrifuged to obtain  
 CC a supernatant portion, which is then heated before being reconstituted  
 CC to precipitate the proteins, and obtaining a second supernatant portion,

CC from which nucleic acids are precipitated. The isolated nucleic acids  
 CC are then dissolved. The method provides a rapid means of preparing a  
 CC sample for amplification so that multiple analytes can be detected and  
 CC differentiated within a relatively short time period (typically less  
 CC than 5 hours with the novel pre-processing step taking less than 5  
 minutes). Typical applications of nucleic acid amplification include  
 CC detection of infections in patients, foodstuffs and for  
 CC diagnostic/forensic or quality control purposes, to discriminate between  
 CC multiple potential infectious pathogens, to diagnose genetic disorders or  
 CC to identify genetic variances.  
 XX Sequence 24 BP; 6 A; 5 C; 5 G; 8 T; 0 other;

Query Match 2.1%; Score 20.8; DB 19; Length 24;  
 Best Local Similarity 91.7%; Pred. No. 3.4e+04; Indels 0; Gaps 0;  
 Matches 22; Conservative 0; Mismatches 2;

OY 91 ggcttggaaatcaactccgcaga 114  
 |||||||||  
 Db 24 GGCTTGAATTACTCAGCAGCA 1

RESULT 12  
 ID AAV31446/C  
 ID AAV31446 standard; DNA; 24 BP.  
 AC AAV31446;  
 DT 11-AUG-1998 (first entry)  
 DE Campylobacter nucleic acid sequence amplifying primer CFO4R.  
 KW Salmonella; microorganism; detection; multiple analyte; PCR primer;  
 KW *Yersinia*; *Escherichia coli*; Campylobacter; ss.  
 XX OS Synthetic.  
 OS Campylobacter sp.  
 XX US5756701-A.  
 PN  
 PD 26-MAY-1998.  
 XX  
 PR 06-AUG-1996; 96US-0592725.  
 XX 16-JAN-1996; 96US-0587209.  
 PR 06-AUG-1996; 96US-0592725.  
 XX  
 PA (GULL-) GULL LAB INC.  
 XX  
 PI Coombs J, Glass MJ, Malmstrom SL, Wu L;  
 DR WPI; 1998-321634/28.

XX PT Nucleic acid probes and primers - for detecting *Salmonella*, *Yersinia*  
 PT or *E. coli*  
 XX Claim 5; Column 17; 21pp; English.

CC This primer is used for the PCR amplification of Campylobacter nucleic  
 CC acid sequences. The invention provides nucleic acid probes and primers  
 CC for detecting *Salmonella*, *Yersinia* or *E. coli*. It provides methods and  
 CC apparatus for detecting and discriminating multiple analytes within a  
 CC test sample. The methods are simple, user-friendly, cost effective and  
 CC fast. The methods and the probes and primer sequences are used for  
 CC detecting the corresponding microorganisms in clinical samples.  
 XX Sequence 24 BP; 6 A; 5 C; 5 G; 8 T; 0 other;

Query Match 2.1%; Score 20.8; DB 19; Length 24;  
 Best Local Similarity 91.7%; Pred. No. 3.4e+04; Indels 0; Gaps 0;  
 Matches 22; Conservative 0; Mismatches 2;

SQ	QY	91 ggctttagaatcaactccgcgaca 114 	Db	24 GGTCTTGAATTAACTCAGCAGCA 1
	24 GGCCTTGAATTAACTCAGCAGCA 1		RESULT 13	QY
XX	AAV25942/C	XX	RESULT 14	91 ggctttagaatcaactccgcgaca 114 
XX	AAV25942 standard; DNA; 24 BP.	XX	DE	
XX	AAV25942;	XX	ID	GGTCTTGAATTAACTCAGCAGCA 1
XX	AC	XX	AAV20847/C	
XX	XX	XX	ID	AAV20847 standard; DNA; 24 BP.
DT	15-JUL-1998 (first entry)	XX	AC	AAV20847;
DE	Oligonucleotide PCR primer CFO4R gene.	XX	XX	AAV20847;
XX	Sequence-specific; probe; enterohaemorrhagic; Escherichia coli;	XX	01-JUL-1998 (first entry)	01-JUL-1998 (first entry)
KW	Salmonella; Campylobacter; Shigella; Yersinia; beta-globin;	XX	DE	Campylobacter CFO4R gene PCR primer.
KW	gastroenteritis; PCR primer; ss.	XX	XX	Escherichia coli strain O157:H7; detection; microorganism; infection;
OS	Syntetic.	XX	KW	enterohaemorrhagic; PCR primer; ss.
OS	Campylobacter sp.	OS	OS	Synthetic.
XX	US575344-A.	OS	OS	Campylobacter sp.
XX	19-MAY-1998.	XX	XX	US575344-A.
PD	PP	XX	XX	14-APR-1998.
XX	07-AUG-1996; 96US-0689235.	XX	PD	PR 07-AUG-1996; 96US-0689236.
XX	16-JAN-1996; 96US-0587209.	XX	XX	PR 16-JAN-1996; 96US-0587209.
PR	07-AUG-1996; 96US-0689235.	XX	XX	PR 07-AUG-1996; 96US-0689236.
XX	(GULL-) GULL LAB INC.	PA	PA	(GULL-) GULL LAB INC.
XX	XX	XX	XX	XX
PR	Coombs J, Glass MJ, Malmstrom SL, Wu L;	PT	PT	Coombs J, Glass MJ, Malmstrom SL, Wu L;
PR	WPI; 1998-311393/27.	XX	XX	WPI; 1998-260031/23.
PT	Distinguishing between similar nucleic acid samples - using sequence-specific probes e.g. between enterohaemorrhagic and normal Escherichia coli	PT	PT	Probes for detecting Escherichia coli strain O157:H7 - useful for diagnosis of enterohaemorrhagic Escherichia coli infection(s)
PT	Example 3; Column 17; 21pp; English.	XX	XX	Example 3; Column 17; 21pp; English.
PS	The present sequence represents a PCR primer used in an example of the present invention. The present invention describes a method for detecting mismatches between first and second nucleic acid sequences having at least one base difference. The method comprises: (a) obtaining at least one labelled probe consisting of an oligonucleotide sequence comprising the probes and the sample, and (c) detecting hybridising the probes and the sample, and (c) detecting hybridising the probes and the nucleic acid sequences. The method and probes may be used for diagnosis of enterohaemorrhagic E. coli infections. The methods and the materials permit the detection and discrimination of multiple analytes.	CC	CC	The present sequence represents a PCR primer used in an example of the present invention. The present invention describes probes used in the detection of Escherichia coli strain O157:H7 in a sample. The method of detection comprises: (a) obtaining at least 1 probe specifically given in the specification, labelled with a label that permits probe detection when hybridised to a complementary nucleic acid sequence which is specific for a nucleic acid sequence of the microorganism; (b) hybridising the probes and the sample, and (c) detecting hybrids comprising the probes and the nucleic acid sequences. The method and probes may be used for diagnosis of enterohaemorrhagic E. coli infections. The methods and the materials permit the detection and discrimination of multiple analytes.
XX	Example 3; Column 17; 21pp; English.	CC	CC	Example 3; Column 17; 21pp; English.
CC	Query Match 2.1%; Score 20.8; DB 19; Length 24; Best Local Similarity 91.7%; Pred. No. 3.4e+04; Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0; Sequence 24 BP; 6 A; 5 C; 5 G; 8 T; 0 other;	CC	CC	Query Match 2.1%; Score 20.8; DB 19; Length 24; Best Local Similarity 91.7%; Pred. No. 3.4e+04; Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0; Sequence 24 BP; 6 A; 5 C; 5 G; 8 T; 0 other;
CC	Probe/first sequence hybrids. The method can be used to distinguish between similar DNA/RNA sequences in a sample, especially to distinguish enterohaemorrhagic E. coli O157:H7 from other E. coli strains e.g. in stool samples from people suffering from gastroenteritis, caused specifically by enterohaemorrhagic E. coli. Use of the method shortens the time between sample preparation to obtaining results, than has been possible with previous similar procedures.	CC	CC	Probe/first sequence hybrids. The method can be used to distinguish between similar DNA/RNA sequences in a sample, especially to distinguish enterohaemorrhagic E. coli O157:H7 from other E. coli strains e.g. in stool samples from people suffering from gastroenteritis, caused specifically by enterohaemorrhagic E. coli. Use of the method shortens the time between sample preparation to obtaining results, than has been possible with previous similar procedures.
CC	Sequence 24 BP; 6 A; 5 C; 5 G; 8 T; 0 other;	CC	CC	Sequence 24 BP; 6 A; 5 C; 5 G; 8 T; 0 other;
CC	XX	CC	CC	XX
CC	Query 91 ggctttagaatcaactccgcgaca 114 	Db	Db	24 GGTCTTGAATTAACTCAGCAGCA 1
CC	Db	24 GGTCTTGAATTAACTCAGCAGCA 1	RESULT 15	Db

DE dGMP-specific aptamer clone #19.  
XX KW  
XX Polymeric biomolecule; aptamer; ss.  
OS Synthetic.  
PN WO200071755-A2.  
XX XX  
PD 30-NOV-2000.  
XX  
PF 25-MAY-2000; 2000WO-US14401.  
XX PR 25-MAY-1999; 99US-0135863.  
XX PA (PRAE-) PRAELUX INC.  
XX  
PI Kwagh J, Macklin JJ, Mitsis PG, Ulmer KM;  
XX DR WPI; 2001-016410/02.

XX

Sequencing a polymeric biomolecule, such as a polynucleotide, polysaccharide or polypeptide, comprises separating a terminal monomer from the polymeric biomolecule and identifying the separated terminal monomer using an aptamer -

XX PS Claim 37; Fig 15; 123pp; English.

CC The present invention relates to a new method for sequencing a polymeric biomolecule. The method involves separating a terminal monomer from the polymeric biomolecule and identifying the separated terminal monomer using an aptamer. The method is useful for sequencing a polymeric biomolecule such as a polynucleotide, a polysaccharide or a polypeptide. The method is also useful for developing aptamers.

XX Sequence 44 BP; 9 A; 6 C; 19 G; 10 T; 0 other;

PS Query Match 2.1%; Score 20 8; DB 22; Length 44;  
Best Local Similarity 70.0%; Pred. No. 3.9e+04; Mismatches 0; Indels 0; Gaps 0;  
Matches 28; Conservative 0; Mismatches 12;

QY 747 tgcataatgggtttatatagttaatgttattatcca 786  
||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 4 tgacaccactgggtggatggtagggttgaaatca 43

Search completed: April 17, 2002, 02:17:16  
Job time: 3512 sec

Copyright (c) 1993 - 2000 Compugen Ltd. OM nucleic - nucleic search, using sw model

#### SUMMARIES

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

Copyright (c) 1993 - 2000, The Sanger Institute

OM nucleic - nucleic search, using sw model

Run on: April 17, 2002, 01:23:59 ; See

Title:	US-09-439-311-1
Perfect score:	999
Sequence:	1 attaacacaatgttgacgc. . . . .
Scoring table:	IDENTITY_NUC Gapop 10.0 , Gapext 1.0
Searched:	351203 seqs, 113239999 residues
Total number of hits	satisfying chosen parameters

#### ALIGNMENTS

```

Sequence 174, App
Sequence 62, Appl
Sequence 174, App
Sequence 19, Appl
Sequence 20, Appl
Sequence 2, Appl
Sequence 8, Appl
Sequence 127, App
Sequence 6, Appl
Sequence 72, Appl
Sequence 72, Appl
Sequence 72, Appl

```

Query Match 2.7%; Score 26.8; DB 4; Length 30;  
 Best Local Similarity 93.3%; Pred. No. 82;  
 Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy	289	caagatggcaaaactttaaaacaagaact	318
Db	30	CAAGATGGACAAGTTAAACAGAACCT	1

RESULT 4  
 US-09-406-147-34  
 ; Sequence 34, Application US/09406147  
 ; Patent No. 6270974  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Shultz, John W  
 ; CURRENT APPLICATION NUMBER: US/09/358,972  
 ; CURRENT FILING DATE: 1999-07-22  
 ; EARLIER APPLICATION NUMBER: 09/252,436  
 ; EARLIER FILING DATE: 1999-02-18  
 ; EARLIER APPLICATION NUMBER: 09/042,287  
 ; EARLIER FILING DATE: 1998-03-13  
 ; NUMBER OF SEQ ID NOS: 290  
 ; SOFTWARE: PatentIn Ver. 2.0  
 ; SEQ ID NO: 103  
 ; LENGTH: 30  
 ; TYPE: DNA  
 ; ORGANISM: Campylobacter jejuni  
 ; FEATURE:  
 ; OTHER INFORMATION: probe to Campylobacter jejuni  
 ; US-09-358-972-103

Query Match 2.7%; Score 26.8; DB 4; Length 30;  
 Best Local Similarity 93.3%; Pred. No. 82;  
 Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy	289	caagatggcaaaactttaaaacaagaact	318
Db	1	caagatggcaaaactttaaaacaagaact	30

RESULT 3  
 US-09-406-147-32/c  
 Sequence 32, Application US/09406147  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Shultz, John W  
 ; CURRENT APPLICATION NUMBER: US/09/358,972  
 ; CURRENT FILING DATE: 1999-07-22  
 ; NUMBER OF SEQ ID NOS: 290  
 ; SOFTWARE: PatentIn Ver. 2.0  
 ; SEQ ID NO: 34  
 ; LENGTH: 30  
 ; TYPE: DNA  
 ; ORGANISM: Campylobacter jejuni  
 ; US-09-406-147-34

Query Match 2.7%; Score 26.8; DB 4; Length 30;  
 Best Local Similarity 93.3%; Pred. No. 82;  
 Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy	289	caagatggcaaaactttaaaacaagaact	318
Db	1	caagatggcaaaactttaaaacaagaact	30

RESULT 5  
 US-08-587-209-6/c  
 ; Sequence 6, Application US/08587209  
 ; Patent No. 5612473  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Wu, Lixinian  
 ; APPLICANT: Coombs, Jana  
 ; APPLICANT: Malmstrom, Sharon L.  
 ; APPLICANT: Gliss, Michael J.  
 ; TIME OF INVENTION: Methods and Apparatus for Preparing, Amplifying,  
 ; NUMBER OF SEQUENCES: 30  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: David O. Seeley, Esq.  
 ; ADDRESSEE: Workman, Nydegger & Seeley  
 ; STREET: 1000 Eagle Gate Tower  
 ; CITY: Salt Lake City  
 ; STATE: Utah  
 ; ZIP: 84111

COMPUTER READABLE FORM:

US-09-406-147-32  
 LENGTH: 30  
 TYPE: DNA  
 ORGANISM: Campylobacter jejuni  
 US-09-406-147-32

MEDIUM TYPE: Diskette, 3.50 inch,  
 MEDIUM TYPE: 1.44 Mb storage  
 COMPUTER: IBM compatible  
 OPERATING SYSTEM: MS-DOS  
 SOFTWARE: WordPerfect 6.0a for WINDOWS  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/587,209  
 FILING DATE: 16-JAN-1996  
 CLASSIFICATION: 435  
 INFORMATION FOR SEQ ID NO: 6:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 24 base Pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: DNA  
 US-08-587-209-6

Query Match 2.1%; Score 20.8; DB 1; Length 24;  
 Best Local Similarity 91.7%; Pred. No. 3e+03; 0; Mismatches  
 Matches 22; Conservative 0; Indels 0; Gaps 0;  
 QY 91 ggcttttagaaatcaactccgcaga 114  
 ||||||| ||||| ||||| |||||  
 Db 24 GGCTTAGAATTACTCGCAGCA 1

RESULT 6  
 US-08-689-235-6/c  
 sequence 6, Application US/08689236  
 Patent No. 575344  
 GENERAL INFORMATION:  
 APPLICANT: Wu, Linxian  
 APPLICANT: Coombs, Jana  
 APPLICANT: Malmstrom, Sharon L.  
 APPLICANT: Glass, Michael J.  
 APPLICANT: Coombs, Jana  
 APPLICANT: Malmstrom, Sharon L.  
 APPLICANT: Glass, Michael J.  
 TITLE OF INVENTION: Methods and Apparatus for Preparing, Amplifying, and Discriminating Multiple Analytes  
 NUMBER OF SEQUENCES: 30  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: David O. Seeley, Esq.  
 ADDRESSEE: Workman, Nydegger & Seeley  
 STREET: 1000 Eagle Gate Tower  
 STREET: 60 East South Temple  
 CITY: Salt Lake City  
 STATE: Utah USA  
 COUNTRY: USA  
 ZIP: 84111

COMPUTER READABLE FORM:  
 MEDIUM TYPE: Diskette, 3.50 inch,  
 MEDIUM TYPE: 1.44 Mb storage  
 COMPUTER: IBM compatible  
 OPERATING SYSTEM: MS-DOS  
 SOFTWARE: WordPerfect 6.0a for WINDOWS  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/689,235  
 FILING DATE: 16-JAN-1996  
 CLASSIFICATION: 435  
 INFORMATION FOR SEQ ID NO: 6:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 24 base Pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: DNA  
 US-08-689-235-6

Query Match 2.1%; Score 20.8; DB 1; Length 24;  
 Best Local Similarity 91.7%; Pred. No. 3e+03; 0; Mismatches  
 Matches 22; Conservative 0; Indels 0; Gaps 0;  
 QY 91 ggcttttagaaatcaactccgcaga 114  
 ||||||| ||||| ||||| |||||  
 Db 24 GGCTTAGAATTACTCGCAGCA 1

RESULT 7  
 US-08-689-235-6/c  
 sequence 6, Application US/08689235  
 Patent No. 575344  
 GENERAL INFORMATION:  
 APPLICANT: Wu, Linxian  
 APPLICANT: Coombs, Jana  
 APPLICANT: Malmstrom, Sharon L.  
 APPLICANT: Glass, Michael J.  
 APPLICANT: Coombs, Jana  
 APPLICANT: Malmstrom, Sharon L.  
 APPLICANT: Glass, Michael J.  
 TITLE OF INVENTION: Methods and Apparatus for Preparing, Amplifying, and Discriminating Multiple Analytes  
 NUMBER OF SEQUENCES: 30  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: David O. Seeley, Esq.  
 ADDRESSEE: Workman, Nydegger & Seeley  
 STREET: 1000 Eagle Gate Tower  
 STREET: 60 East South Temple  
 CITY: Salt Lake City  
 STATE: Utah USA  
 COUNTRY: USA  
 ZIP: 84111

COMPUTER READABLE FORM:  
 MEDIUM TYPE: Diskette, 3.50 inch,  
 MEDIUM TYPE: 1.44 Mb storage  
 COMPUTER: IBM compatible  
 OPERATING SYSTEM: MS-DOS  
 SOFTWARE: WordPerfect 6.0a for WINDOWS  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/689,235  
 FILING DATE: 16-JAN-1996  
 CLASSIFICATION: 435  
 INFORMATION FOR SEQ ID NO: 6:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 24 base Pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: DNA  
 US-08-689-235-6

Query Match 2.1%; Score 20.8; DB 1; Length 24;  
 Best Local Similarity 91.7%; Pred. No. 3e+03; 0; Mismatches  
 Matches 22; Conservative 0; Indels 0; Gaps 0;  
 QY 91 ggcttttagaaatcaactccgcaga 114  
 ||||||| ||||| ||||| |||||  
 Db 24 GGCTTAGAATTACTCGCAGCA 1

RESULT 8  
 US-08-689-235-6/c  
 sequence 6, Application US/08689235  
 Patent No. 575344  
 GENERAL INFORMATION:  
 APPLICANT: Wu, Linxian  
 APPLICANT: Coombs, Jana  
 APPLICANT: Malmstrom, Sharon L.  
 APPLICANT: Glass, Michael J.  
 APPLICANT: Coombs, Jana  
 APPLICANT: Malmstrom, Sharon L.  
 APPLICANT: Glass, Michael J.  
 TITLE OF INVENTION: Methods and Apparatus for Preparing, Amplifying, and Discriminating Multiple Analytes  
 NUMBER OF SEQUENCES: 30  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: David O. Seeley, Esq.  
 ADDRESSEE: Workman, Nydegger & Seeley  
 STREET: 1000 Eagle Gate Tower  
 STREET: 60 East South Temple  
 CITY: Salt Lake City

STATE: Utah  
COUNTRY: USA

**COMPUTER READABLE FORM:**

MEDIUM TYPE: Diskette, 3.50 inch  
MEDIUM TYPE: 1.44 Mb storage  
COMPUTER: IBM compatible

OPERATING SYSTEM: MS-DOS  
SOFTWARE: WordPerfect 6.0a for WINDOWS

CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/692,725  
FILING DATE: 16-JAN-1996

CLASSIFICATION: 435  
INFORMATION FOR SEQ ID NO: 6:  
SEQUENCE CHARACTERISTICS:

SEQUENCE CHARACTERISTICS:  
LENGTH: 24 base pairs  
TYPE: nucleic acid

US-08-692-725-6  
NUMBER OF STUDENTS: 10  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Mark M. Friedman c/o Robert Sheinbein

STREET: 2940 Birchtree space lane  
CITY: Silver Spring  
STATE: Maryland

COUNTRY: United States of America  
ZIP: 20906  
Country: United States

DB :  
24 GGTCTTGAATTAACTCAGGAGCA 1  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 1 44 megabyte, 3.5" microdisk  
COMPUTER: Twinhead Slimmode-890TX

RESULT : 9  
OPERATING SYSTEM: MS DOS version 6.2,  
OPERATING SYSTEM: Windows version 3.11  
SOFTWARE: Word Windows version 2.0

US-08-692-726-6/c  
; Sequence 6, Application US/8692726  
; Patent No. 5,846,783  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/431,527A

APPLICATION NUMBER: 10-00000  
FILING DATE: 01/01/2010  
ATTORNEY/AGENT INFORMATION:  
APPLICANT: Coombs, Jana  
APPLICANT: Malmstrom, Sharon L.  
APPLICANT: Glass, Michael J.

TITLE OF INVENTION: Methods and Apparatus for Preparing, Amplifying, and Discriminating Multiple Analytes  
; TITLE OF INVENTION: Amplifying, and Discriminating Multiple Analytes  
; NUMBER OR SPECIMENS: 30  
NAME: Friedman, Mark M.  
REGISTRATION NUMBER: 33,883

NUMBER OF SEQUENCES: 30  
CORRESPONDENCE ADDRESS: ADDRESSEE: DAVID O. SEELEY, Esq.  
TELECOMMUNICATION INFORMATION:  
REFERENCE/DOCKET NUMBER: 12878  
TELEPHONE: 977-3-6938541

ADDRESSEE: Workman, Nydegger & Seeley  
STREET: 1000 Eagle Gate Tower  
STREET: 60 East South Temple  
TELEFAX: 972-3-6938542  
TELEX:  
INFORMATION FOR GEN TO NO. 7.

CITY: Salt Lake City STATE: Utah LENGTH: 58  
INFORMATION FOR JEW NO. 1;  
SEQUENCE CHARACTERISTICS:

TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear

US-08-431-527A-7  
; MEDIUM TYPE: Diskette, 3.50 inch,  
; MEDIUM TYPE: 1.44 Mb storage  
; COMPUTER: IBM compatible

OPERATING SYSTEM: MS-DOS  
SOFTWARE: WordPerfect 6.0a for WINDOWS  
CUSTOMER SUPPORT: 1-800-222-1234

---

Query Match 2.1%; Score 20.8; DB 2; Length 58;  
Best Local Similarity 60.7%; Ped. No. 4.3e+03;

APPLICATION NUMBER: US-08/692,726  
FILING DATE: 06-AUG-1996

CLASSIFICATION: 435  
PRIORITY APPLICATION DATA: 09/597,200  
ADDITIONAL NUMBER: 09/597,200

SEQUENCE CHARACTERISTICS:  
LENGTH: 24 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
  
; Sequence 30, Application US/09214278  
; Patent No. 6291210  
; GENERAL INFORMATION:  
APPLICANT: Sakano, Seiji  
APPLICANT: Itoh, Akira



APPLICANT: yang, Meijia  
APPLICANT: Knight, James  
APPLICANT: Kalbfleisch, Theodore  
TITLE OF INVENTION: IDENTIFICATION AND COMPARISON OF  
TITLE OF INVENTION: PROTEIN-PROTEIN INTERACTIONS THAT OCCUR IN POPULATIONS  
TITLE OF INVENTION: AND IDENTIFICATION OF INHIBITORS OF THESE INTERACTORS  
NUMBER OF SEQUENCES: 122

ADDRESSEE: Penne & Edmonds  
STREET: 115 Avenue of the Americas  
CITY: New York

COUNTRY: USA  
ZIP: 10036/2711  
COMPUTER SPEAKER FORM.

**CORE-DRIVEN NUMBERED** **FORMAT:**  
**CORE-DRIVEN TYPE:** Diskette  
**COMPUTER:** IBM Compatible  
**COMPATIBLE** **DISKETTE**

OVERLAPPING STREAMS: 000  
SOFTWARE: FASTSQL Version 2.0  
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US08/874,825  
FILING DATE: 13-JUN-1997  
CLASSIFICATION: 435

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/6663,824  
FILING DATE: 14-JUN-1996

ATTORNEY/AGENT INFORMATION:  
NAME: MISTOCK, S. Leslie  
REGISTRATION NUMBER: 18-872

REFERENCE/DOCKET NUMBER: 7934-045  
TELECOMMUNICATION INFORMATION:  
TPI-FPONC - 212-780-8000

TELEFAX: 212-865-8864  
TELEX: 66141 PENNIE  
INTERCONNECTIONS CORP. AND TRADING CO., INC.

SEQUENCE CHARACTERISTICS: 110.  
LENGTH: 39 base pairs

**TYPE:** nucleic acid  
**STRANDEDNESS:** single  
**TOPOLOGY:** linear

MOLECULE TYPE: DNA  
8-874-825-118

every Match Similarity Score 20; DB 3; Length 39;

tches 23; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

700 aggtaatggatccatccatcgaggat 735  
735 ||||| ||||| ||||| ||||| |||||  
39 AGGTCAAGTTGCCATTCTCAGATGGTCAT 12

LT 15

8-450-905B-7/C  
quence 7, Application US/08450905B  
tent No. 5356301

**GENERAL INFORMATION:**  
**APPLICANT:** Stem Cell Inhibiting Proteins  
**NAME OF INVENTION:** Stem Cell Inhibiting Proteins

NUMBER OF SEQUENCES: 178  
CORRESPONDENCE ADDRESS:  
*Department of Biochemistry,  
University of Texas at Austin,  
Austin, TX 78712-0275*

**STREET:** 60 State Street  
**CITY:** Boston

STATE: MA  
ZIP: 02109  
COMPUTER READABLE FORM:

COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patient Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:

~ Wed Apr 17 07:36:45 2002

us-09-439-311-1.rni

THIS PAGE BLANK (USPTO)

copyright (c) 1993 - 2000	Gencore version 4.5	Compugen Ltd.
<b>Om nucleic - nucleic search, using sw model</b>		
Run on:	April 17, 2002, 01:16:14 ; Search time 1464.96 Seconds	(without alignments)
	7327.688 Million cell updates/sec	
Title:	US-09-439-311-1	
Perfect score:	999	
Sequence:	1 attaacacaaatgtgcagc.....ttaaaaatgtatggtagat	999
Scoring table:	IDENTITY_NUC	
	Gapop 10.0 , Gapext 1.0	
Searched:	11351937 seqs, 5372889281 residues	
Total number of hits satisfying chosen parameters:	111874	
Minimum DB seq length:	0	
Maximum DB seq length:	60	
Post-processing:	Minimum Match 0%	
	Maximum Match 100%	
Listing first 45 summaries		
Database :	EST:*	
	1: em_estfun:*	
	2: em_esthum:*	
	3: em_estin:*	
	4: em_estom:*	
	5: em_estpl:*	
	6: em_estba:*	
	7: em_estro:*	
	8: em_estov:*	
	9: em_htc:*	
	10: gb_est1:*	
	11: gb_est2:*	
	12: gb_htc:*	
	13: gb_gss:*	
	14: em_gss_fun:*	
	15: em_gss_hum:*	
	16: em_gss_inv:*	
	17: em_gss_bln:*	
	18: em_gss_pro:*	
	19: em_gss_rod:*	
	20: em_gss_vrt:*	
	21: em_gss_other:*	
<b>Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.</b>		
<b>SUMMARIES</b>		
Result No.	Query Score	Match Length DB ID Description
c 1	23.6 2.4	50 10 AU104183 AU104183 AU104183 AU104183
c 2	21.6 2.2	60 10 AA608932 AA608932 aa03d01s
c 3	21.1 2.1	52 10 AA122474 AA122474 mq27h10.r
c 4	20.8 2.1	59 10 AW657832 AW657832 NF014A01R
c 5	20.8 2.1	60 11 BF658864 BF658864 NF050H02P
c 6	20.6 2.1	58 10 AA874675 AA874675
c 7	20.4 2.0	51 13 AZ812517 AZ812517 M0079C15
c 8	20.2 2.0	55 10 AU014315 AU014315 AU014315
c 9	20.2 2.0	50 10 AU103731 AU103731 AU103731
c 10	20.2 2.0	54 13 AZ951541 AZ951541 2M0220G15
c 11	20.2 2.0	58 11 BF131272 BF131272 601819529
c 12	20.2 2.0	59 11 W38842 W38842 zb28c08.rl
<b>ALIGNMENTS</b>		
RESULT	1	
AU104183/C	AU104183	50 bp mRNA
LOCUS	AU104183 Sugano Homo sapiens cDNA library EST	Homo sapiens cDNA clone
DEFINITION	KAT0693, mRNA sequence.	
ACCESSION	AU104183	
VERSION	AU104183.1	GI:13553704
KEYWORDS	EST.	
SOURCE	human.	
ORGANISM	Homo sapiens	
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.	
REFERENCE	1 (bases 1 to 50)	
AUTHORS	Suzuki,Y., Tsunoda,T., Taira,H., Mizushima-Sugano,J., Sese,J., Ratai,H., Ota,T., Isogai,T., Tanaka,T., Nakamura,Y., Morishita,S., Okubo,K., Suyama,A. and Sugano,S.	
TITLE	Fine structural analysis of transcription start sites of human mRNAs using full-length enriched and 5'-end enriched cDNA libraries	
JOURNAL	Unpublished (2001)	
COMMENT	Contact: Yuraka Suzuki Department of Virology Institute of Medical Science, University of Tokyo 4-6-1, Shirokanedai, Minatoku, Tokyo 108-6339, Japan Email: yuzukuni.tokyo.ac.jp Suzuki,Y., Yoshitomo-Nakaya,K., Maruyama,K., Suyama,A. and Sugano,S., Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).	
FEATURES	source	
	1. .50	
	/organism="Homo sapiens"	
	/db_xref="taxon:9606"	
	/clone="KAT0693"	
	/clone_id="Sugano H. et al. 2001"	
BASE COUNT	12 a	12 c
	4 g	22 t
ORIGIN		



JOURNAL		COMMENT	
ACCESSION	AW687832.2	EST.	Unpublished (2000)
VERSION			Contact: Harrison MJ
KEYWORDS			Plant Biology Division
SOURCE			The Samuel Roberts Noble Foundation
ORGANISM	Medicago truncatula		2510 Sam Noble Parkway, Ardmore, OK 73402, USA
REFERENCE	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Rosidae; eurosids I; Fabales; Fabaceae; Papilionoideae; Trifoliace; Medicago; eurosids I; Fabales; Fabaceae; Papilionoideae; Trifoliace; Medicago truncatula		Tel: 580 221 7325
AUTHORS	Watson,B.S., Shin,H.-S., Lopez-Meyer,M., Scott,A.D., Harris,A.R., Gonzales,R.A., Bell,C.J., Flores,H.R., Inman,J.T., Weller,J.W., May,G.D. and Paiva,N.L.		Fax: 580 221 7380
JOURNAL	Expressed Sequence Tags from the Samuel Roberts Noble Foundation		Email: mjharrison@noble.org
COMMENT	Unpublished (2000)		Insert Length: 60 Std Error: 0.00
	On Apr 14, 2000 this sequence version replaced 91:7562568.		Plate: 060 row: H column: 02
	Contact: Paiva NL		Seq primer: TCACACAGGAACAGCTATGAC.
FEATURES	Plant Biology Division		Location/Qualifiers
source	The Samuel Roberts Noble Foundation 2510 Sam Noble Parkway, Ardmore, OK 73402, USA		1. .60
	Tel: 580 221 7317		/organism="Medicago truncatula"
	Fax: 580 221 7380		/ab_xref="taxon:3880"
	Email: nipaiva@noble.org		/clone="NF014R01RT"
	Insert length: 721 Std Error: 0.00		/clone_1lib="Developing root"
	Plate: 014 low: A column: 01		/dev_stage="root development"
	Seq primer: TCACACAGGAACAGCTATGAC.		/note="Vector: Lambda Zap; Total RNA was extracted from non-inducted roots of plants grown in 1 mM nitrate medium. Samples were taken at four time points (approximately two days, one, two and six weeks post germination) representing early seedling growth to nitrogen limitation."
BASE COUNT	19 a 9 c 13 g 18 t		
ORIGIN			
Query Match	2.1%	Score 20.8; DB 10; Length 59;	Best Local Similarity 59.6%; Pred. No. 6.9e+05; Mismatches 19; Indels 0; Gaps 0;
Best Local Similarity	70.0%	Pred. No. 6.9e+05; Mismatches 12; Indels 0; Gaps 0;	Matches 28; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
Matches	28; Conservative		
Qy	822 caatgtgtaaagatacactggatctaaggcttaaa 861		Qy 76 tcacagactcagtccagggtttagaaactcaactccggagaaatgtatgc 122
Db	54 CATTGCAATAGCAGAACACAAGGTGTCTAACTTCA 15		Db 47 TCAGGACTNNTNAGGTTGATGGNCAGCTANACNGNCTGTC 1
RESULT	5		
LOCUS	BR538864/C		RESULT 6
DEFINITION	BF638864 60 bp mRNA		Query Match 2.1%; Score 20.8; DB 11; Length 60;
ACCESSION	NF050H02PL1F1026		Best Local Similarity 59.6%; Pred. No. 6.9e+05; Mismatches 19; Indels 0; Gaps 0;
VERSION			Matches 28; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
KEYWORDS			
SOURCE			
ORGANISM	Mus musculus		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.		
AUTHORS	1 (bases 1 to 58) Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubreuil,T., Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., More,B., Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and Waterton,R.		
JOURNAL	The WashU-HMM Mouse EST Project		
COMMENT	Unpublished (1996)		
	Contact: Marra M/WMouse EST Project		
	WashU-HMM Mouse EST Project		
	Washington University School of Medicine		
	4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108		
	Tel: 314 286 1800		
	Fax: 314 286 1810		
	Email: mouseest@watson.wustl.edu		
	This clone is available royalty-free through LILNL; contact the IMAGE Consortium (info@image.lnl.gov) for further information.		
	MG:664196		
	Trace considered overall poor quality		
	Sequence reversed clone: similarity on wrong strand		
	Seq primer: -28m3 rev1 ET from Amersham		
	High quality sequence stop: 1.		

FEATURES source	Location/Qualifiers
	musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource ( <a href="http://www.Jax.org/resources/documents/dnarecs/">http://www.Jax.org/resources/documents/dnarecs/</a> ). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD2 (g147321149b AF229072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL1-Gold (Stratagene) cells and selected for ampicillin resistance.
BASE COUNT ORIGIN	19 a 18 c 2 g 19 t
Query Match	2.1%; Score 20.6; DB 10; Length 58;
Best Local Similarity	62.7%; Pred. No. 7.7e+05;
Matches	32; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
Oy	208 atcttgcaactcgagaataaggctatgtatggaaacttaaaatcttagat 258
Db	51 ATGTTGGATGGGCCAGGTCTAATGAATGAGTGGTTAAATTAAAT 1
RESULT	7
LOCUS	AZ812517 51 bp DNA GSS 20-FEB-2001
DEFINITION	2M0079C15F Mouse 10kb plasmid UGGCLM library Mus musculus genomic
ACCESSION	AZ812517
VERSION	AZ812517.1 GI:12981041
KEYWORDS	GSS.
SOURCE	house mouse.
ORGANISM	Mus musculus
REFERENCE	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
AUTHORS	Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausen, A., and Wright, D., Weiss, R.
TITLE	Mouse whole genome scaffolding with paired end reads from 10kb plasmid insert
JOURNAL	Unpublished (2000)
COMMENT	Contact: Robert B. Weiss University of Utah Genome Center 8m, 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA Tel: 801 585 5605 Fax: 801 585 7177 Email: ddunn@genetics.utah.edu
	Insert Length: 10000 Std Error: 0.00
	Plate: 0079 row: C column: 15
	Seq primer: CGTGCTTAACGAGGCCAGT
	Class: plasmid ends
	High quality sequence stop: 51.
	Location/Qualifiers
FEATURES source	1. .51
	/organism="Mus musculus"
	/strain="C57BL/6J"
	/db_xref="taxon:10090"
	/clone="UUGC2M0079C15"
	/clone_1ib="Mouse 10kb plasmid UGGCLM library"
	/sex="Male"
	/lab_host="E. coli strain XL10-Gold, T1-resistant, F+"
	/note="Vector: pMD2uv; Purified genomic DNA from M."
BASE COUNT ORIGIN	9 a 18 c 11 9 13 t
Query Match	2.0%; Score 20.4; DB 10; Length 55;
RESULT	8
LOCUS	AU014315 55 bp mRNA EST 03-AUG-1998
DEFINITION	AU014315 Schizosaccharomyces pombe late log phase cDNA
ACCESSION	AU014315
VERSION	AU014315.1 GI:3369106
KEYWORDS	EST.
SOURCE	fission yeast.
ORGANISM	Schizosaccharomyces pombe
REFERENCE	Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes; Schizosaccharomyces pombe; Schizosaccharomycetaceae; Schizosaccharomyces.
AUTHORS	1 (bases 1 to 55) Morimoto, M. and Mita, K.
TITLE	Identification of expressed sequence tags of Schizosaccharomyces pombe
JOURNAL	Unpublished (1998)
COMMENT	Contact: Mitsuaki Morimoto Genome Research Group National Institute of Radiological Sciences 9-1, Anagawa-4-chome, Inage-ku, Chiba, Chiba 263-8555, Japan Email: morimotol@rs.nirs.go.jp
FEATURES source	1. .55
	/organism="Schizosaccharomyces pombe"
	/strain="972"
	/db_xref="taxon:4896"
	/clone="spc09537"
	/clone_1ib="Schizosaccharomyces pombe late log phase cDNA"
	/sex="h minus"
	/note="Vector: M13mp19; the cDNA library of Schizosaccharomyces pombe was prepared by cloning cDNA into the small site of M13mp19 DNA and the direction of DNA sequences was not always from 5' to 3'. The cDNA data of Schizosaccharomyces pombe are available for searching on the World Wide Web. (URL, <a href="http://www.nirs.go.jp">http://www.nirs.go.jp</a> )"
BASE COUNT ORIGIN	24 a 2 c 9 g 20 t
Query Match	2.0%; Score 20.4; DB 10; Length 55;



FEATURES	source
source	<p>Tissue procurement: ATCC</p> <p>cDNA Library Preparation: CLONETECH Laboratories, Inc.</p> <p>CDNA Library Arrangement by: The T.M.A.G.E. Consortium (LLNL)</p> <p>DNA Sequencing by: Incyte Genomics, Inc.</p> <p>Clone distribution: MGC clone distribution information can be found through the T.M.A.G.E. Consortium/LLNL at:</p> <p><a href="http://image.llnl.gov">http://image.llnl.gov</a></p> <p>Plate: LCLM866 row: j column: 07.</p>
Location/Qualifiers	<p>1..58</p>
/organism	"Homo sapiens"
/db_xref	"taxon:9606"
/clone	"IMAGE:051302"
/clone_lid	"NIH_MGC_58"
/tissue_type	"hyperparathyroidia"
/lab_host	"DH10B (T1 phage-resistant)"
/note	"Organ: kidney; Vector: pDNR-LIB (Clontech); Site_1: SfiI (ggccgccttcggcc); Site_2: SfiI (ggccgttatcgcc); double-stranded cDNA was prepared from cell line RNA. 5' and 3' adaptors were used in cloning as follows: 5' adaptor sequence: 5'-CACGCCCATATGCGCC-3', and 3' adaptor sequence: 5'-ATTCTAGGGCGAGGGGGGACATG-dT(30)BN-3', (where B = A, C, G or N = A, C, G, T, or T). Average insert size 1.35 kb (range 0.4 - 4.0 kb). 15/15 colonies contained inserts by PCR. This library was enriched for full-length clones and was constructed by Clontech Laboratorie (Palo Alto, CA)." 1 others
BASE COUNT	22 a 9 c 9 g 26 t
ORIGIN	
Query Match	2.0%; Score 20.2; DB 11; Length 58;
Best Local Similarity	63.3%; Pred. No. 9. 6e+05; Matches 31; Conservative 0; Mismatches 18; Indels 0; Gaps 0;
'Matches	
Qy	543 tgttaggacttataaaactacacgatcgatcgaaattttaattt 591
Db	49 TGTTATATAGATAGATATTAATATGTGATGTTAGGATTAATAT 1
RESULT	12
LOCUS	w38842_c 59 bp mRNA
DEFINITION	zb2gc08_r1 Soares,Parathyroid tumor_NDHPA Homo sapiens EST
LOCUS	w38842_c 59 bp mRNA
DEFINITION	zb2gc08_r1 Soares,Parathyroid tumor_NDHPA Homo sapiens cDNA clone
IMAGE	304910 5'; similar to gb:M90516
GLUCOSAMINE--FRUCTOSE-6-PHOSPHATE AMINOTRANSFERASE (HUMAN); mRNA sequence.	
ACCESSION	W38842
VERSION	W38842.1
VERSTON	GI:1320547
KEYWORDS	EST.
SOURCE	Human.
ORGANISM	Homo sapiens
REFERENCE	Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
AUTHORS	1 (bases 1 to 59)
Hiller,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M., Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M., Parsons,J., Riffin,L., Rohlfing,T., Soares,M., Tan,F., Trevaskis,E., Waterston,R., Williamson,A., Wohlgemann,P. and Wilson,R.	
TITLE	The WashU-Merck EST Project
JOURNAL	Unpublished (1995)
COMMENT	Contact: Wilson RK Washington University School of Medicine 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108 Tel: 314 286 1800 Fax: 314 286 1810 Email: <a href="mailto:est@watson.wustl.edu">est@watson.wustl.edu</a>
FEATURES	<p>This clone is available royalty-free through LLNL; contact the IMAGE Consortium (<a href="http://image.llnl.gov">http://image.llnl.gov</a>) for further information.</p> <p>Trace considered overall poor quality</p> <p>Seq primer: mob.REA+ET</p> <p>High quality sequence stop: 54.</p> <p>Location/Qualifiers</p>
source	<p>LCLM866 row: j column: 07.</p> <p>1..59</p> <p>/organism "Homo sapiens"</p> <p>/db_xref "GDB:1248320"</p> <p>/clone "IMAGE:304910"</p> <p>/clone_lid "Soares,parathyroid_tumor_NDHPA"</p> <p>/tissue_type "parathyroid tumor"</p> <p>/dev_state "adult"</p> <p>/lab_host "DH10B (ampicillin resistant)"</p> <p>/note "Organ: parathyroid gland; Vector: pTR73D (Pharmacia ) with a modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer [5'-TGTTACCACTGAGGGGGGGGCAATTGTTTGTGTTTGTGTTTGTGTTTGTGTT-3'] double-stranded cDNA was size selected, ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of a modified pTR73 vector (Pharmacia). Library went through one round of normalization to a COT = 5. Library constructed by Benito Soares and M.Ratima Bondalgi. RNA from sporadic parathyroid adenomas was also provided by Dr. Stephen Marx, National Institute of Diabetes and Digestive and Kidney Diseases, NIH."</p>
BASE COUNT	23 a 5 c 10 g 19 t
ORIGIN	
Query Match	2.0%; Score 20.2; DB 11; Length 59;
Best Local Similarity	63.3%; Pred. No. 9. 6e+05; Matches 31; Conservative 0; Mismatches 18; Indels 0; Gaps 0;
'Matches	
Qy	550 cttagatattaaactacacgatcgatcgaaatttgatagt 598
Db	51 CTGTCCTTAAATCACAATCAGAGCTGCTATTAATTCATATTG 3
RESULT	13
LOCUS	AZ434413 54 bp DNA
DEFINITION	AZ434413 54 bp DNA 1M0220118R Mouse 10kb plasmid UGCL1M library GSS
ACCESSION	AZ434413
VERSION	AZ434413.1
KEYWORDS	GS.
SOURCE	house mouse.
ORGANISM	Mus musculus
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
AUTHORS	1 (bases 1 to 54)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.	
TITLE	Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL	Unpublished (2000)
COMMENT	Contact: Robert B. Weiss University of Utah Genome Center University of Utah Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
FEATURES	<p>Fax: 801 585 5606</p> <p>Email: <a href="mailto:odunugene@utah.edu">odunugene@utah.edu</a></p> <p>Insert length: 10000 Std Error: 0.00</p> <p>Plate: 0220 row: I column: 18</p> <p>Seq primer: CACACGGAACAGCTATGACC</p> <p>Class: Plasmid ends</p> <p>High quality sequence stop: 54.</p> <p>Location/Qualifiers</p>
source	<p>1..54</p> <p>/organism "Mus musculus"</p> <p>/strain "C57BL/6J"</p>

FEATURES	
source	vector to vector length is 57.
	Location/Qualifiers
1. .56	Location/Qualifiers
/clone lib="Mouse 1kb plasmid UGCM1 library"	
/sex "Male"	
/lab_host="E. coli strain XLI0-Gold, T1-resistant, F-"	
/note="Vector: pND42nv; Purified genomic DNA from M-	
musculus C5BL/6J (male) was obtained from the Jackson	
laboratory Mouse DNA Resource	
(http://www.Jax.org/resources/documents/dnares/).	The DNA
was hydrodynamically sheared by repeated passage through a	was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA	0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4	was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were	polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The	ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to	adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel	10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative	electrophoresis. Vector DNA was prepared from a derivative
of pND2 (g1473214 gb AF129072 ), a copy-number	of pND2 (g1473214 gb AF129072 ), a copy-number
inducible derivative of plasmid R1. The vector was ligated	inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and	with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to	purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into	adapted vector DNA, and transformed into
chemically competent E. coli XLI0-Gold (Stratagene) cells	chemically competent E. coli XLI0-Gold (Stratagene) cells
and selected for ampicillin resistance."	and selected for ampicillin resistance."
RIGIN	11 c
BASE COUNT	6 g
ORIGIN	18 t
Query Match	2.0%
Best Local Similarity	61.5%
Matches	32;
AUTHORS	Conservative
DEFINITION	0; Mismatches
ACCESSION	0;
VERSION	Indels
KEYWORDS	0;
SOURCE	Gaps
ORGANISM	0;
RESULT	14
FOCUS	AW780772
DEFINITION	56 bp mRNA
LOCUS	sl185c06.y1 Gm-c1037
REFERENCE	Gm-c1037-803 5', mRNA sequence.
AUTHORS	
ACCESSION	AW780772
VERSION	.1
KEYWORDS	GI:7795447
SOURCE	
ORGANISM	
RESULT	14
FOCUS	AW780772
DEFINITION	56 bp mRNA
LOCUS	EST
REFERENCE	12-MAY-2000
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	14
FOCUS	AW780772
DEFINITION	56 bp mRNA
LOCUS	EST
REFERENCE	12-MAY-2000
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647 Human chromosome 18q21 from exon-trapping Homo sapiens
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647 Human chromosome 18q21 from exon-trapping Homo sapiens
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647 Human chromosome 18q21 from exon-trapping Homo sapiens
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
RESULT	15
FOCUS	AF149647
DEFINITION	AF149647
LOCUS	AF149647
REFERENCE	
AUTHORS	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	

Search completed: April 17, 2002, 02:14:13  
Job time: 3479 sec

OM of: US-09-439-311-2 to: N\_Geneseq\_1101.\* out\_format : pfs  
 Date: Apr 17, 2002 3:13 AM  
 About: Results were produced by the GenCore software, version 4.5,  
 Copyright: (c) 1993-2000 Compugen Ltd.

## Command line parameters:

```
-MODEL=frame+Pdn.model -DBV=xlp
-O/cgn2-1/uspto_spool/US9439311/runat_16042002_134011_11729/app_query.fasta_1.395
-DB=N_Geneseq_1101 -QFMT=fastq -SUFFIX=qng -GAPEXT=0.000
-GAPLEN=4.000 -MINMATCH=100 -LOOPLEN=0.000 -LOOPEXT=0.000
-OGAPOP=.500 -OGAPEXT=0.050 -XGAPOP=10.000 -XGAPEXT=0.500
-FGAPOP=6.000 -FGAPEXT=7.000 -RGAPOP=10.000 -YGAPEXT=0.500
-DELOP=6.000 -DELEXTP=7.000 -START=1 -MATRIX=blossom2
-TRANS:human40.gcd -LIST=45 -DOCALIGN=200 -THR_SCORE=PCT
-THR_MAX=100 -THR_MIN=0 -ALIGN=15 -MODE=LOCAL -OUTFMT=pfs
-NCPU=6 -ICPU=3 -LONGLOG -NO_XLPXY -WAIT -THREADS=1
```

## Search information block:

Query: US-09-439-311-2

Query length: 333

Database sequences: N\_Geneseq\_1101:\*

Database length: 42862619

Search time (sec): 170.970000

## score\_list:

Sequence	Strd	Orig	ZScore	EScore	Len	Documentation	
/STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAAB6891	-		50.00	100.69	1.6e+03	30	
/STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAAB6892	+		50.00	100.69	1.6e+03	30	
/STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAAB3188	-		50.00	100.69	1.6e+03	30	
/STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAAB9390	+		50.00	100.69	1.6e+03	30	
/STD2/gcdata/geneseq/geneseq/NA1998.DAT:AAV23196	+		88.52	7.4e-03	59	L	
/STD2/gcdata/geneseq/geneseq/NA1998.DAT:AAV4813	+		43.00	85.32	1.1e+04	51	H
/STD2/gcdata/geneseq/geneseq/NA1998.DAT:AAV19519	+		43.00	85.32	1.1e+04	51	DR
/STD2/gcdata/geneseq/geneseq/NA1998.DAT:AAV00234	+		41.00	82.48	1.6e-04	50	XX
/STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAZ66924	+		40.00	79.47	2.4e+04	59	S
/STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAZ00254	+		40.00	79.32	2.4e+04	60	T
/STD2/gcdata/geneseq/geneseq/NA2001.DAT:AAF0806	+		40.00	79.32	2.4e+04	60	T
/STD2/gcdata/geneseq/geneseq/NA2001.DAT:AAI30690	+		39.00	83.80	1.4e+04	31	H
/STD2/gcdata/geneseq/geneseq/NA1998.DAT:AAV56429	-		39.00	80.03	2.2e+04	47	H
/STD2/gcdata/geneseq/geneseq/NA1999.DAT:AAV1884	-		39.00	80.03	2.2e+04	47	H
/STD2/gcdata/geneseq/geneseq/NA1999.DAT:AAV9197	-		39.00	80.03	2.2e+04	47	H
/STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAH9904	-		39.00	80.03	2.2e+04	47	H
/STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAH7971	-		39.00	80.03	2.2e+04	47	H
/STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAH79509	-		39.00	80.03	2.2e+04	47	H
/STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAH2343	-		39.00	80.03	2.2e+04	47	H
/STD2/gcdata/geneseq/geneseq/NA2001.DAT:AAH16472	-		39.00	77.97	2.9e+04	59	H
/STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAZ37149	-		38.00	81.73	1.8e+04	33	C
/STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAZ2765	-		38.00	79.98	2.2e+04	51	S
/STD2/gcdata/geneseq/geneseq/NA2001.DAT:AAH19904	+		38.00	77.78	2.9e+04	51	C
/STD2/gcdata/geneseq/geneseq/NA1995.DAT:AAV05069	-		38.00	77.43	3.1e-04	53	C
/STD2/gcdata/geneseq/geneseq/NA1995.DAT:AAV53649	-		38.00	77.43	3.1e-04	53	C
/STD2/gcdata/geneseq/geneseq/NA1995.DAT:AAV23184	-		38.00	76.46	3.5e+04	59	C
/STD2/gcdata/geneseq/geneseq/NA1995.DAT:AAZ05956	+		38.00	76.31	3.5e+04	60	C
/STD2/gcdata/geneseq/geneseq/NA1998.DAT:AAH05080	+		37.00	83.11	1.5e-04	24	C
/STD2/gcdata/geneseq/geneseq/NA1998.DAT:AAV1446	-		37.00	83.11	1.5e-04	24	C
/STD2/gcdata/geneseq/geneseq/NA1998.DAT:AAV25942	-		37.00	83.11	1.5e-04	24	C
/STD2/gcdata/geneseq/geneseq/NA1998.DAT:AAV18769	+		37.00	79.43	2.4e+04	36	C
/STD2/gcdata/geneseq/geneseq/NA1997.DAT:AAV63391	-		37.00	78.48	2.7e+04	40	C
/STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAJ73050	+		37.00	76.63	3.4e-04	49	T
/STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAJ77507	-		37.00	76.27	3.5e+04	51	XX
/STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAJ71013	-		37.00	75.42	4.0e+04	56	M
/STD2/gcdata/geneseq/geneseq/NA1998.DAT:AAV77663	+		37.00	75.11	4.1e+04	58	H
/STD2/gcdata/geneseq/geneseq/NA1998.DAT:AAV18769	+		36.00	74.51	4.4e+04	51	H
/STD2/gcdata/geneseq/geneseq/NA1997.DAT:AAV63490	-		36.00	74.76	4.3e+04	51	H
/STD2/gcdata/geneseq/geneseq/NA1997.DAT:AAV73784	-		36.00	74.76	4.3e+04	51	H

Sequence	Strd	Orig	ZScore	EScore	Len	Documentation
/STD2/gcdata/geneseq/geneseq/NA2001.DAT:AAH79776	-		36.00	74.76	4.3e+04	51
/STD2/gcdata/geneseq/geneseq/NA2001.DAT:AAU68898	-		36.00	74.76	4.3e+04	51
/STD2/gcdata/geneseq/geneseq/NA1995.DAT:AAQ97415	+		36.00	74.41	4.5e+04	53

seq\_name: /STD2/gcdata/geneseq/geneseq/NA2000.DAT:AAAB6891  
 seq\_documentation\_block:  
 ID AAA86891 standard; DNA; 30 BP.  
 XX  
 AC AAA86891;  
 XX DT 15-JAN-2001 (first entry)  
 DE Probe to *Campylobacter jejuni*.  
 XX  
 KW Detection; nucleic acid hybrid; depolymerisation; analysis; SNP;  
 single nucleotide polymorphism; identification; primer; target; mutation;  
 genotyping; medical marker diagnostic; primer; target; mutation;  
 genetic disease; ss.  
 OS Campylobacter jejuni.  
 XX  
 PN WO2000049180-11.  
 XX PD 24-AUG-2000.  
 XX PR 18-FEB-2000; 990US-0252436.  
 PR 21-JUL-1999; 990US-0358972.  
 PR 25-AUG-1999; 990US-0383316.  
 XX PA (PROM-) PROMEGA CORP.  
 PI Schultz JW, Lewis MK, Leippe D, Mandrekar M, Kephart D, Rhodes RB;  
 Andrews CA, Hartnett JR, Gu T, Olson RJ, Wood KV, Welch R;  
 XX DR WPI: 2000-565377/52.  
 PT Determining presence or absence of a predetermined endogenous nucleic  
 acid sequence by using an enzyme that depolymerizes the 3' end of an  
 oligonucleotide probe hybridized to a target sequence to release  
 identifier nucleotides  
 XX PS Example; Page 321; 389pp; English.  
 XX CC The present invention describes a method (M1) for determining the  
 presence or absence of a predetermined endogenous nucleic acid target  
 sequence (ENR). The method comprises hybridising a probe having an  
 identifier nucleotide (IN) with ENR which is treated with an enzyme  
 that depolymerises the 3' end of hybridised ENR to release the INs.  
 M1 is used for determining the number of known sequence repeats present  
 in a nucleic acid target sequence in a nucleic acid sample. The method  
 is also useful for determining whether a nucleic acid target sequence in  
 a sample is an allele from a homozygous or heterozygous locus. The  
 method is also useful for detection of mutations, translocations and  
 SNPs in nucleic acids (including those associated with genetic disease),  
 determination of viral load, species identification, sample  
 contamination, and analysis of forensic samples. AA86791 to AA87079  
 and AAB12817 represent sequence which are used in the exemplification of  
 the present invention.  
 N.B. There is a discrepancy between the SEQ ID NO: and sequences given  
 in the examples, and the SEQ ID NO: and sequences given in the sequence  
 listing from the present invention.

alignment\_scores:

Quality: 50.00 Length: 10 Gaps: 0

Percent Similarity: 100.00 Percent Identity: 100.00

alignment\_block:

US-09-439-311-2 x AAA86891/rev ..

Align seq 1/1 to reverse of: AAA86891 from: 1 to: 30

97 GluAspGlyGlnSerLeuIysThrArgThr 106

||||||| ||||| ||||| ||||| |||||

30 CAAGATGGACAAACTTAAACAGAACT 1

seq\_name: /SIDS2/gcqdata/geneseq/geneseq/NA2000.DAT:AAA86892

seq\_documentation\_block:

ID AAA86892 standard; DNA; 30 BP.

AC AAA86892;

DT 15-JAN-2001 (first entry)

DE Probe to *Campylobacter jejuni*.

XX

KW Detection; nucleic acid hybrid; depolymerisation; analysis; SNP; single nucleotide polymorphism; identification; viral load; probe; genotyping; medical marker diagnostic; primer; target; mutation; genetic disease; ss.

XX

OS *Campylobacter jejuni*.

PN WO200049180-A1.

XX

PD 24-AUG-2000.

XX

PF 18-FEB-2000; 2000WO-US04242.

XX

PR 18-FEB-1999; 99US-0252436.

XX

PR 21-JUL-1999; 99US-0358972.

XX

PR 25-AUG-1999; 99US-0383316.

XX

PA (PROM-) PROMEGA CORP.

XX

PI Shultz JW, Lewis MK, Leippe D, Mandrekar M, Kephart D, Rhodes RB;

PI Andrews CA, Hartnett JR, Gu T, Olson RJ, Wood KV, Welch R;

DR XX

PS WPI; 2000-565377/52.

XX

PT Determining presence or absence of a predetermined endogenous nucleic acid sequence by using an enzyme that depolymerizes the 3' end of an

PT oligonucleotide probe hybridized to a target sequence to release

PT identifier nucleotides -

XX

PS Example; Page 321; 389pp; English.

CC The present invention describes a method for determining the presence or absence of a predetermined endogenous nucleic acid target sequence (ENAT). The method comprises hybridising a probe having an

CC identifier nucleotide (IN) with ENAT which is treated with an enzyme

CC that depolymerises the 3' end of hybridised NA to release the INs.

CC MI is used for determining the number of known sequence repeats present in a nucleic acid target sequence in a nucleic acid sample. The method is also useful for determining whether a nucleic acid target sequence in a sample is an allele from a homozygous or heterozygous locus. The method is also useful for detection of mutations, translocations and SNPs in nucleic acids (including those associated with genetic disease), determination of viral load, species identification, sample contamination, and analysis of forensic samples. AAA8709 and AAB1281 represent sequence which are used in the exemplification of the present invention.

N.B. There is a discrepancy between the SEQ ID NO: and sequences given in the examples, and the SEQ ID NO: and sequences given in the sequence listing from the present invention.

Sequence 30 BP; 16 A; 4 C; 5 G; 5 T; 0 other;

alignment\_scores:

Quality: 50.00

Ratio: 5.000

Gaps: 0

Percent Similarity: 100.000

Percent Identity: 100.000

alignment\_block:

US-09-439-311-2 x AAA86892 ..

Align seq 1/1 to: AAA86892 from: 1 to: 30

97 GluAspGlyGlnSerLeuIysThrArgThr 106

||||||| ||||| ||||| |||||

1 CAAGATGGACAACTTAAACAGAACT 30

seq\_name: /SIDS2/gcqdata/geneseq/geneseq/NA2000.DAT:AAA93188

seq\_documentation\_block:

ID AAA93188 standard; DNA; 30 BP.

AC AAA93188;

DT 11-JAN-2001 (first entry)

DE *Campylobacter jejuni* interrogation probe 11451.

XX

KW *Campylobacter jejuni*; nucleic acid detection; genomic typing; mutation detection; viral load determination; species identification; forensic analysis; probe; ss.

XX

OS *Campylobacter jejuni*.

XX

PN WO200049179-A1.

XX

PR 24-AUG-2000.

XX

PR 18-FEB-1999; 99US-0252436.

XX

PR 21-JUL-1999; 99US-0358972.

XX

PR 27-SEP-1999; 99US-0406147.

XX

PA (PROM-) PROMEGA CORP.

XX

PI Shultz JW, Lewis MK, Leippe D, Mandrekar M, Kephart D, Rhodes RB;

PI Andrews CA, Hartnett JR, Gu T, Olson RJ, Wood KV, Welch R;

DR XX

PS Claim 47; Page 187; 230pp; English.

The present sequence is an interrogation probe which was used to detect a segment of the genome of *Campylobacter jejuni*. This was performed as part

CC of a method for determining the presence of a known exogenous nucleic acid target sequence in a nucleic acid sample. The method comprises

CC adding a treated sample with a depolymerising enzyme which releases one

CC or more nucleotides from the 3'-end of a hybridised nucleic acid probe. The method is used for assaying nucleic acids for a particular native or

CC mutant sequence, and for genomic typing. It is useful for detecting mutations, translocations, and single nucleotide polymorphisms, determination of viral load, species identification, detection of sample contamination, and analysis of forensic samples. Compared with previous methods of detecting nucleic acid hybrids, the new method has higher sensitivity without the need for radiochemicals or electrophoresis. It is quantitative, highly reproducible and can be automated. The method can

CC reliably detect as few as 10 copies of a virus in a sample, and is capable of providing multiple analyses in a single assay (multiplex assay).

XX Sequence 30 BP; 5 A; 5 C; 4 G; 16 T; 0 other;

XX alignment\_scores:

Quality:	50.00	Length:	10
Ratio:	5.00	Gaps:	0

Percent Similarity: 100.000 Percent Identity: 100.000

alignment\_block:  
US-09-439-311-2 x AAA93188/rev ..

Align seq 1/1 to reverse of: AAA93188 from: 1 to: 30

97 GlnAspGlyGlnSerLeuLysThrArgRhr 106  
|||||||.....|||||||.....|||||||

30 CAAGATGGACAAAGTTAAACACAGACT 1

seq\_name: /SIDS2/gcgdata/geneseq/geneseqn/NA2000.DAT:AAA93190

seq\_documentation\_block:  
ID AAA93190 standard; DNA; 30 BP.

XX AC AAA93190;

XX DT 11-JAN-2001 (first entry)

XX DE Campylobacter jejuni interrogation probe 11450.

XX KW Campylobacter jejuni; nucleic acid detection; genomic typing; mutation detection; viral load determination; species identification; forensic analysis; probe; ss.

XX OS Campylobacter jejuni.

XX PN WO200009179-A1.

XX PD 24-AUG-2000.

XX PF 18-FEB-2000; 2000WO-US04176.

\*XX PR 18-FEB-1999; 99US-0352436.

PR 21-JUL-1999; 99US-0358972.

PR 27-SEP-1999; 99US-0406147.

XX PA (PROM-) PROMEGA CORP.

XX PI Shultz JW, Lewis MK, Leippe D, Mandrekar M, Kephart D, Rhodes RB; Andrews CA, Hartnett JR, Gu T, Olson RJ, Wood KV, Welch R;

DR XX WPI: 2000-549282/50.

XX PT Detecting the presence of predetermined exogenous nucleic acid target sequence useful for e.g. genotyping, comprises depolymerizing the 3' end of an oligonucleotide probe hybridized to a nucleic acid target sequence -

PT sequence -

PS Claim 47; Page 187; 230PP; English.

CC The present sequence is an interrogation probe which was used to detect a segment of the genome of *Campylobacter jejuni*. This was performed as part of a method for determining the presence of a known exogenous nucleic acid target sequence in a nucleic acid sample. The method comprises admixing a treated sample with a depolymerising enzyme which releases one or more nucleotides from the 3'-end of a hybridised nucleic acid probe. The method is used for assaying nucleic acids for a particular native or mutant sequence, and for genomic typing. It is useful for detecting mutations, translocations, and single nucleotide polymorphisms, determination of viral load, species identification, detection of sample contamination, and analysis of forensic samples. Compared with previous methods of detecting nucleic acid hybrids, the new method has higher sensitivity without the need for radiochemicals or electrophoresis. It is quantitative, highly reproducible and can be automated. The method can reliably detect as few as 10 copies of a virus in a sample, and is capable of providing multiple analyses in a single assay (multiplex assay).

CC alignment\_scores:

Quality:	50.00	Length:	10
Ratio:	5.00	Gaps:	0

Percent Similarity: 100.000 Percent Identity: 100.000

alignment\_block:  
US-09-439-311-2 x AAA93190 ..

Align seq 1/1 to: AAA93190 from: 1 to: 30

97 GlnAspGlyGlnSerLeuLysThrArgRhr 106  
|||||||.....|||||||.....|||||||

1 CAAGATGGACAAAGTTAAACACAGACT 30

seq\_name: /SIDS2/gcgdata/geneseq/geneseqn/NA1998.DAT:AAV23196

seq\_documentation\_block:  
ID AAV23196 standard; DNA; 59 BP.

XX AC AAV23196;

XX DT 28-JUL-1998 (first entry)

XX DE Lactococcus lactis constitutional promoter CP29.

XX KW Lactococcus lactis; constitutional promoter; optimise; spacer; artificial promoter library; gene expression; ds.

XX OS Synthetic Lactococcus lactis.

OS Lactococcus lactis.

XX FH Key Location/Qualifiers

FT promoter 4..59

FT /\*tag\* a

FT /standard\_name= "Constitutional promoter"

XX PN WO9807846-A1.

XX PD 26-FEB-1998.

XX PR 25-AUG-1997; 97WO-DK00342.

XX DR 23-AUG-1996; 96DK-0000886.

XX PA (JENS/) JENSEN P R.

XX PI Hammer K, Jensen PR;

XX DR WPI; 1998-179062/16.

XX PT New artificial promoter libraries - containing consensus promoter sequences and variable spacers, used to generate promoters for optimising expression of genes

XX PS Claim 28; Page 52; 89PP; English.

CC This is a *Lactococcus lactis* constitutional promoter sequence used in the construction of an artificial promoter library of the invention. The artificial promoter library for a selected organism or group of organisms comprise a mixture of double-stranded DNA fragments, the sense strands of which comprise at least half of two consensus sequences of efficient promoters from the organism or group of organisms and surrounding or intermediate nucleotide sequences (spacers) of variable length in which at least 7 nucleotides are selected randomly, with the proviso that previously known promoter sequences and promoter sequences isolated from natural sources are not included. This promoter library can be used in a

method of optimising the expression of a gene in a microorganism. The method comprises selecting a set of promoters covering a range of promoter activities in relatively small steps of activity change from such an artificial promoter library and cloning the set of promoters into the organism placing in each clone the gene under the control of at least one promoter from the set and growing the selected clones and screening them to find the one showing optimised flux of product formation. Promoters covering wide ranges of activities, including very strong promoters can be generated which can be used for optimising expression of genes.

Sequence 59 BP; 15 A; 9 C; 16 G; 19 T; 0 other;

SQ

alignment\_scores:

	Quality:	Length:	Gaps:	
Percent Similarity:	46.00	13	0	
Ratio:	4.600			
Percent Identity:	76.923			

alignment\_block:

US-09-439-311-2 x AAV23196 ..

Align seg 1/1 to : AAV23196 from: 1 to: 59

seq\_name: /STD\$2/gcdata/geneseq/geneseqn/NA1999.DAT:AAX34813

seq\_documentation\_block:

ID AAX34813; standard; DNA; 51 BP.

AC AAX34813;

XX

DT 06-JUL-1999 (first entry)

DE Human ZSIG-11 DNA specific primer ZC13735.

XX

KW Secretory protein; ZSIG-11; ligand polypeptide; testis; endoprotease; prohormone convertase; fertility; therapeutic; human; PCR primer; ss.

XX

OS Synthetic.

OS Homo sapiens.

XX

PN WO9916870-A1.

XX

PD 08-APR-1999.

XX

PR 29-SEP-1998; 98WO-US20449.

XX

PR 19-MAY-1998; 98US-0085966.

PR 29-SEP-1997; 97US-0000327.

PR 29-SEP-1997; 97US-0039897.

PR 19-MAY-1998; 98US-0081310.

XX

(ZYMO ) ZYMOGENETICS INC.

PA Sheppard PO;

XX

DR WPI; 1999-263692/22.

XX

PT Polynucleotide encoding a human secretory protein, ZSIG-11.

XX

PS Example 9; Page 108; 113pp; English.

The invention relates to a human secretory protein, ZSIG-11. Host cells containing a vector comprising the ZSIG-11 nucleic acid are used for the recombinant expression of the protein. ZSIG-11 is a novel ligand polypeptide and specific antibodies can be used to detect its presence in a biological sample. Probes derived from ZSIG-11 nucleotide sequences can also be used in detection of ZSIG-11 RNA. ZSIG-11 is expressed at high levels in testis, and could be used to identify/study prohormone

CC convertses or endoproteases that exhibit testis specificity.

CC Antagonists, including antibodies, are useful for inhibiting or eliminating the function of ZSIG-11. It is possible that ZSIG-11 and its antagonists will be useful as fertility inducing therapeutics.

CC Sequences AAX34800-21 represent PCR primers for amplifying the ZSIG-11 DNA.

XX Sequence 51 BP; 17 A; 5 C; 19 G; 10 T; 0 other;

SQ

alignment\_scores:

	Quality:	Length:	Gaps:	
Percent Similarity:	3.583	16	0	
Ratio:	75.00			
Percent Identity:	50.000			

alignment\_block:

US-09-439-311-2 x AAX34813 ..

Align seg 1/1 to : AAX34813 from: 1 to: 51

seq\_name: /STD\$2/gcdata/geneseq/geneseqn/NA1999.DAT:AAX19519

seq\_documentation\_block:

ID AAX19519; standard; DNA; 51 BP.

XX

AC AAX19519;

XX

DT 07-JUN-1999 (first entry)

XX

DE Human lipocalin homologue zlipol PCR primer ZC13\_735.

XX

KW Human; lipocalin; testis; mammary gland; breast tumour; zlipol; breast cancer; emphysema; skin disease; reproduction; anti-inflammatory; antimicrobial; PCR primer; ss.

XX

OS Synthetic.

OS Homo sapiens.

XX

PN WO9907740-A2.

XX

PD 18-FEB-1999.

XX

PF 06-AUG-1998; 98WO-US16425.

XX

PR 06-AUG-1997; 97US-0054867.

XX

PA (ZYMO ) ZYMOGENETICS INC.

XX

PI Conklin DC;

XX

DR WPI; 1999-167367/14.

XX

PT New lipocalin homologue designated zlipol - whose expression is restricted to testis and mammary gland tissues, particularly breast tumour tissue, used to, e.g. predict tumour aggressiveness.

XX

PS Example 5; Page 89; 94pp; English.

XX

The present sequence represents a PCR primer for lipocalin homologue, zlipol. The lipocalin homologue, zlipol, is specifically expressed in testis and mammary gland, particularly breast tumour tissue. Based on this tissue distribution, zlipol may be used as a diagnostic for breast carcinomas and as a tool for predicting tumour aggressiveness. Agonists can be used for transportation of small hydrophobic molecules either in vivo or in vitro, and so are useful in specifically promoting the growth and/or development of testis-specific cell lineages in culture. Zlipol can be used to identify inhibitors. Zlipol proteins can also be used to prepare antibodies (which can be linked to toxins), and can serve as immunogens. Zlipol proteins can be used as a delivery and encapsulation

CC system to transport and/or stabilise small lipophilic molecules, e.g. to protect from gut pH and digestive enzymes. They can also be used to bind CC small fatty acids in blood or tissues to modulate their biological function, e.g. to transport retinoids or steroids to receptors, in particular as therapy for breast cancer, emphysema and diseases of the skin. They may also play an important role in reproduction. Other uses include anti-inflammatory responses, and antimicrobial activities. CC zípol nucleic acid sequences may be used for gene therapy to increase CC inhibit zípol activity to derive probes and primers, to derive antisense sequences, and to detect genetic abnormalities.

XX Sequence 51 BP; 17 A; 5 C; 19 G; 10 T; 0 other;

alignment\_scores:  
Quality: 43.00 Length: 16  
Ratio: 3.583 Gaps: 0  
Percent Similarity: 75.000 Percent Identity: 50.000

alignment\_block:  
US-09-439-311-2 x AAX19519 ..

Align seg 1/1 to: AAX19519 from: 1 to: 51

253 GlyylvalvalileGlylylvalalaPtySerAspGlyAspGluAngly 268  
||| ||| ::||| |||||::||| ||||::|||  
1 GGTGTAAGCTTGACAAAGAGATTGAGCAAGGACATGAGCAGGGT 48

seq\_name: /SIDS2/egedata/geneseq/geneseq/NA1998.DAT:AAV00234

seq\_documentation\_block:  
ID AAV00234 standard; DNA; 50 BP.

XX AAV00234;

XX DT 08-JUN-1998 (first entry)

DE Tick vasoactive amine binding protein FS-HBPI reverse PCR primer.

XX Female-specific vasoactive amine binding protein 1; FS-HCPI;

KW histamine; serotonin; assay; antihistamine; anti-inflammatory;

KW insect bite; scorpion bite; dermatitis; vaccine;

KW transgenic animal; tick; PCR; primer; ss.

XX OS Synthetic.

OS Rhipecephalus appendiculatus.

XX PN W09744451-A2.

XX PD 27-NOV-1997.

XX PF 19-MAY-1997; 97WO-GB01372.

XX PR 18-APR-1997; 97GB-0007844.

XX PR 18-MAY-1996; 96GB-0010484.

XX PA (OXFO-) OXFORD VACS LTD.

XX PI Nuttall PA, Paesen GC;

XX DR WPI; 1998-010506/02.

XX New vasoactive amine binding proteins and related nucleic acid,

PT vectors - transformed cells and transgenic animals, used for assaying or removing histamine and as antihistamine or anti-inflammatory agents

XX Example 3; Page 20: 44pp; English.

CC This reverse primer was used with a forward primer (see AAV00233) CC to amplify the coding region (see AAV00227) of Rhipecephalus CC appendiculatus female-specific histamine binding protein 1 CC (FS-HBPI) (see AAV37446), a novel vasoactive amine binding protein CC XX

CC (VABP). The primers were designed so that a SacI site was added CC upstream of the start codon, while the stop codon was replaced by CC a BamHI site, followed by 6 histidine codons and an SpeI site CC comprising a TAG stop codon. The PCR product was ligated into CC transfer vector pACC1291, generating plasmid pACC1291-FSI-HIS. CC FS-HBPI was expressed as a histidine-tagged protein in Spodoptera fruiperda SF21 ovarian cells using a baculovirus expression system. CC VBPs can be used to assay or remove histamine, as an antihistamine CC or anti-inflammatory agent, and in vaccines.

XX Sequence 50 BP; 11 A; 8 C; 14 G; 17 T; 0 other;

alignment\_scores:  
Quality: 41.00 Length: 10  
Ratio: 4.100 Gaps: 0  
Percent Similarity: 100.000 Percent Identity: 70.000

alignment\_block:  
US-09-439-311-2 x AAV00234 ..

Align seg 1/1 to: AAV00234 from: 1 to: 50

262 SerAspGlyAspGluAsnGlySerileuile 271  
|||||||:::|||||:::|||||:::|||  
7 AGTGANGTGATGATGGATCCCTCTCG 36

seq\_name: /SIDS2/egedata/geneseq/geneseq/NA2000.DAT:AAZ96924

seq\_documentation\_block:  
ID AAZ96924 standard; DNA; 59 BP.

XX AAZ96924;

XX DT 14-APR-2000 (first entry)

DE S. cerevisiae gene deletion cassette constructing primer YMR290c-S1.

XX KW Antimycotic; mycosis; immunodepression; AIDS; diabetes; fungicide;

XX KW mycete; gene deletion; PCR primer; ss.

XX OS Saccharomyces cerevisiae.

XX PN WO9955907-A2.

XX PD 04-NOV-1999.

XX PF 22-APR-1999; 99WO-EP02722.

XX PR 24-APR-1998; 98EP-0401007.

XX PR 11-SEP-1998; 98EP-0402254.

XX PA (HMR-) HOECHST MARTON ROUSSEL.

XX PI Diu-Hercend A, Entian K, Koetter P;

XX DR WPI; 2000-105227/09.

XX PT Identifying antimycotic substances useful for drug preparation and PT treatment of mycosis - Examples; Page 71; 86pp; English.

XX The invention provides a method of screening for antimycotic substances CC using essential genes from mycetes or a functionally similar mycete CC gene or the corresponding encoded protein as target. The essential gene CC useful for screening antimycotic substances is selected from the CC following genes: YML114C, YLR186W, YLR115C, YLR222C, YLR243W, YLR272C, YLR275W, YLR276C, YLR317W, YLR359W, YLR373C, YLR424W, YLR437C, YLR440C, YML023C, YML049C, YML077W, YML093W, YML127W, YMR032W, YMR093W, YMR131C, YMR185W, YMR212C, YMR213W, YMR218C, YMR281W, YMR288W, YMR290C, YMR211W, YMR49C, YMR134W, YDR126C, YDR293W, YDR365C, YDR396W, YDR407C, YDR16W, YDR449C, YDR472W, YDR499W, YDR141C, YDR324C, YDR325W, YDR398W, YDR246W,

CC YDR36C, YDR361C, YDR367W, YDR339C, YDR413C, YDR429C, YDR468C, YDR494W,  
 CC YDR527W, YDR286W, YDR201W, YDR434W, YDR181C, YDR331W, YPL035W,  
 CC YPL033W, YPL242W, YPL024W, YPL012W, YPL007C, YPL123W, YPL146C, YPL091C,  
 CC YIL083C, YIL019W, YIL109C, YIL104C, YFL024C, YFL033C, YFL037W, YFL042W,  
 CC YIR010W, YIR015W, YPR048W, YPR072W, YPR082C, YPR085C, YPR105C, YPR112C,  
 CC YPR137W, YPR133W, YPR144C and YPR169W. The method is useful for identifying substances for the preparation of drugs for the treatment of mycosis or prevention in immunodepression states. Drugs containing antimycotic substances are useful for the treatment of mycotic infections which occur during diseases like AIDS or diabetes which may be used for the fabrication of fungicides, especially of fungicides which are harmless for humans and animals, especially of substances which selectively inhibit the growth of specific mycete species only, can also be identified by this method. Sequences AZ296811-296990 represent PCR primers used in construction of S. cerevisiae deletion cassettes.

XX Sequence 59 BP; 8 A; 12 C; 15 G; 24 T; 0 other;

alignment\_scores:  
 Quality: 40.00 Length: 15  
 Ratio: 3.077 Gaps: 0  
 Percent Similarity: 86.667 Percent Identity: 53.333

alignment\_block:  
 US-09-439-311-2 x AAT00254 ..

Align seg 1/1 to: AAT00254 from: 1 to: 59

163 SerLysIleGlyVaLThrArgPheGluGlySerGlnSerPhe 177  
 :::::::::::::::::::::|||||||:::|||||||:|||||||:  
 9 ACGTCTTGGTATTGGCGTTTCACAGGCCAGCTGAAGCTC 53

seq\_name: /SIBS2/ggldata/geneseq/geneseq/NA1995.DAT:AAT00254

seq\_documentation\_block:  
 ID AAT00254 standard; DNA; 60 BP.  
 XX  
 AC AAT00254;  
 XX  
 DT 14-AUG-1996 (first entry)

XX DE Thrombin 60N DNA ligand, clone #31.

XX KW Family 1; family 2; ligand; thrombin; systematic evolution of ligands by exponential enrichment; SELEX; heparin; selection; region of homology; inhibitor; ss.

XX OS Synthetic.

XX PN W09521853-A1.

XX PD 17-AUG-1995.

XX PF 06-FEB-1995; 95W0-0S01458.

XX PR 28-MAR-1994; 94US-0219012.

PR 10-FEB-1994; 94US-0195005.

PR 11-JUN-1990; 90US-0536428.

PR 10-JUN-1991; 91US-0714131.

PR 22-APR-1993; 93US-0061691.

XX (NEKS-) NEXSTAR PHARM INC.

XX PI Gold L, Janjic N, Tasset D;

XX DR WPI; 1995-293073/38.

XX PT Identification of ligands to basic fibroblast growth factor and thrombin - which can be modified for increased in vivo stability

XX PS Claim 39; Page 97; 236pp; English.

XX Sequence 60 BP; 10 A; 11 C; 29 G; 10 T; 0 other;

alignment\_scores:  
 Quality: 40.00 Length: 19  
 Ratio: 2.667 Gaps: 0  
 Percent Similarity: 78.947 Percent Identity: 42.105

alignment\_block:  
 US-09-439-311-2 x AAT00254 ..

Align seg 1/1 to: AAT00254 from: 1 to: 60

204 ThrSerValAlaGlyThaGlyLeuGlyIlaLeuAlaGluGluIleAsnArgAs 220  
 ||:::::|||:::||||||| |||||||||:::|||||||:  
 4 ACCGGGGAGGGCGTAGGGTTGGAGGCGTTCGCCGATGGGTAGGCACGGA 53  
 220 nalaAsp 222  
 ::::|||:  
 54 CTCGGAT 60

seq\_name: /SIBS2/ggldata/geneseq/geneseq/NA2001.DAT:AAF70806

seq\_documentation\_block:  
 ID AAF70806 standard; DNA; 60 BP.  
 XX  
 AC AAF70806;  
 XX  
 DT 20-APR-2001 (first entry)

XX DE Thrombin high affinity ligand #53.

XX KW Ligand; basic fibroblast growth factor; bFGF; gene therapy; vascular; atherosclerosis; angioplasty; stability; ss.

XX OS Unidentified.

XX PN US6177557-B1.

XX PD 23-JAN-2001.

XX PF 05-AUG-1996; 96US-0687421.

XX PR 11-JUN-1990; 90US-0536428.

PR 10-JUN-1991; 91US-0714131.

PR 05-NOV-1992; 92US-097333.

PR 10-FEB-1994; 94US-0195005.

PR 28-MAR-1994; 94US-0219012.

XX PA (NEKS-) NEXSTAR PHARM INC.

XX PI Janjic N, Gold L, Tasset D;

XX DR WPI; 2001-158583/16.

XX PT Novel nucleic acid ligands to basic fibroblast growth factor that are useful as inhibitors of basic fibroblast growth factors and 2-amino modified RNA ligands, exhibit increased in vivo stability

XX The sequences given in AAT00202-25 and AAT00227-57 represent two groups of ligands to thrombin. These sequences were isolated using the single stranded DNA molecules given in AAT00201 and AAT0025 which comprise a 3'ON and a 6'ON variable region, respectively. These ligands were isolated using systematic evolution of ligands by exponential enrichment (SELEX). The selection was conducted in a buffer solution at 37 deg. C. After 12 rounds of selection, no additional improvement in binding was seen. By studying regions of homology between the isolated ligands, a truncated ligand of 38 nucleotides (see AAO98403-04) was identified which retains high affinity binding and inhibits clotting. These ligands are mediators of thrombin and are therefore useful in treating thrombin.

Example 19; Column 59-60; 153pp; English.

The present invention relates to a purified and isolated non-naturally occurring DNA ligands as part of gene therapy treatments and for diagnosing pathogenesis of vascular diseases including initiation and progression of atherosclerosis, acute coronary syndromes, vein graft disease and restenosis following coronary angioplasty. The ligands have improved stability in vivo.

Sequence 60 BP; 10 A; 11 C; 29 G; 10 T; 0 other;

PS	Claim 1; Page 101; 145pp; English.
XX	
CC	The invention relates to the identification of nucleic acid molecules (AA129513-AA13134) from the human genome which include polymorphic sites which can predispose individuals to disease. Various genes from a number of individuals were resequenced and single nucleotide polymorphisms (SNPs) in these genes discovered. The method is useful for predicting the presence, absence or severity of a particular phenotype or disorder (e.g. diabetes) associated with a particular genotype. The nucleic acids containing the polymorphic sites may be useful in forensics and paternity testing.
CC	SQ Sequence 31 BP; 12 A; 4 C; 7 G; 8 T; 0 other;
CC	alignment_scores:
CC	Quality: 40.00 Length: 19
CC	Ratio: 2.667 Gaps: 0
CC	Percent Similarity: 78.947 Percent Identity: 42.105
CC	alignment_block:
CC	US-09-439-311-2 x AAF70805 ..
CC	Align seg 1/1 to: AAF70805 from: 1 to: 60
CC	204 ThrSerValGlyThrGlyLeuGlyAlaLeuAlaGluGluIleLeuAsnArgAs 220
CC	4 AGCGCAGGGCTAGGTTGGAGGCGTGGCGATGNGTAGGCACCGA. 53
CC	220 nAlaAsp 222
CC	54 CTCGGAT 60
CC	seq_name: /S1SS2/gcggdata/geneseq/geneseqn/NA2001.DAT:AA130690
CC	seq_documentation_block:
CC	ID AA130690 standard; DNA; 31 BP.
CC	XX
CC	AC AAT30690;
CC	XX
CC	DT 18-OCT-2001 (first entry)
CC	XX
CC	DE Human single nucleotide polymorphism (SNP) ATM 2.
CC	XX
CC	KW Human; resequence; genotype; disease; forensic; paternity testing; single nucleotide polymorphism; SNP; ss.
CC	XX
CC	OS Homo sapiens. .
CC	XX
CC	FH Key Variation Location/Qualifiers
CC	FT replace(16,G)
CC	FT /*tag= a
CC	FT /standard_name= "single nucleotide polymorphism"
CC	XX
CC	WO20166800-A2.
CC	XX
CC	PD 13-SEP-2001.
CC	XX
CC	PP 07-MAR-2001; 2001WO-US07268.
CC	XX
CC	PR 07-MAR-2000; 2000US-0187510.
CC	PR 22-MAY-2000; 2000US-0206129.
CC	XX
CC	(WHED ) WHITEHEAD INST BIOMEDICAL RES.
CC	XX
CC	PI Cargill M, Ireland JS, Lander ES;
CC	XX
CC	DR WPI; 2001-522952/57.
CC	XX
CC	PT Nucleic acid molecules from the human genome which include polymorphic sites, useful in methods for predicting the presence, absence or severity of a particular phenotype or disorder (e.g. diabetes) associated with a particular genotype
CC	PT
PS	Claim 1; Page 101; 145pp; English.
CC	The invention relates to the identification of nucleic acid molecules (AA129513-AA13134) from the human genome which include polymorphic sites which can predispose individuals to disease. Various genes from a number of individuals were resequenced and single nucleotide polymorphisms (SNPs) in these genes discovered. The method is useful for predicting the presence, absence or severity of a particular phenotype or disorder (e.g. diabetes) associated with a particular genotype. The nucleic acids containing the polymorphic sites may be useful in forensics and paternity testing.
CC	SQ Sequence 31 BP; 12 A; 4 C; 7 G; 8 T; 0 other;
CC	alignment_scores:
CC	Quality: 39.00 Length: 9
CC	Ratio: 4.333 Gaps: 0
CC	Percent Similarity: 100.000 Percent Identity: 77.778
CC	alignment_block:
CC	US-09-439-311-2 x AA130690 ..
CC	Align seg 1/1 to: AA130690 from: 1 to: 31
CC	139 ThrAsnGlnGluPheAsnIleGlyAsr 147
CC	5      :      :      :      :
CC	5 ACAAAAGGAGGATTCGAATTTGGTTC 31
CC	seq_name: /S1SS2/gcggdata/geneseq/geneseqn/NA1998.DAT:AAV56429
CC	seq_documentation_block:
CC	ID AAV56429 standard; DNA; 47 BP.
CC	XX
CC	AC AAV56429;
CC	XX
CC	DT 20-NOV-1998 (first entry)
CC	XX
CC	DE Human ICAM-R cDNA primer #27.
CC	XX
CC	KW Intercellular adhesion molecule; ICAM-R; human; modulator; 14.3.3 family; HSL beta; tubulin; inhibitor; effector; immune response; inflammation; disorder; T cell activation; macrophage; Crohn's disease; adult respiratory distress syndrome; stroke; multiple sclerosis; asthma; rheumatoid arthritis; tumour growth; human immune deficiency virus; infection; diabetes; graft vs. host disease; passive immunisation; KW primer; ss.
CC	XX
CC	OS Synthetic.
CC	OS Homo sapiens.
CC	XX
CC	PN US5773218-A.
CC	XX
CC	PD 30-JUN-1998.
CC	XX
CC	PF 07-JUN-1995; 95US-0482882.
CC	XX
CC	PF 05-AUG-1994; 94US-0286754.
CC	PR 27-JAN-1992; 92US-0827689.
CC	PR 26-MAY-1992; 92US-0889724.
CC	PR 05-JUN-1992; 92US-0894061.
CC	PR 22-JAN-1993; 93US-0009266.
CC	PR 26-JAN-1993; 93WO-US00787.
CC	PR 05-AUG-1993; 93US-0102852.
CC	PR 07-JUN-1995; 95US-0482882.
CC	XX
CC	(ICOS-) ICOS CORP.
CC	XX
CC	PI Gallatin WM, Vazeur R;
CC	XX
CC	DR WPI; 1998-386989/33.
CC	XX
CC	PT Identifying compounds that modulate interaction of intercellular
CC	PT

PT adhesion molecule R - with ligands HS-beta and tubulin using  
 PT two-hybrid assay, useful for treating inflammation, T cell  
 activation etc.

XX Example 13; Column 135-136; 108pp; English.

CC AAV56429-V56434 are primers used in the isolation of a novel human  
 CC intercellular adhesion molecule, ICAM-R. This sequence is used in a  
 CC method which investigates modulators of the interaction between ICAM-R  
 CC and the 14.3.3 family member HSI-beta and tubulin. An anti-ICAM-R  
 CC antibody, can block, inhibit or stimulate ligand/receptor interactions  
 CC involving ICAM-R, particularly its effector functions involved in  
 CC (non)specific immune responses. ICAM-R related agents may be used to  
 CC treat or monitor inflammation, disorders involving T cell activation or  
 CC macrophages, e.g. adult respiratory distress syndrome, stroke, Crohn's  
 CC disease, multiple sclerosis, rheumatoid arthritis, asthma, tumour  
 CC growth, human immune deficiency virus infection, diabetes, graft vs. host  
 CC disease and many others. Antibodies may also be used for passive  
 CC immunisation, for purifying, detecting or quantifying ICAM-R and for  
 CC identifying ICAM-R expressing cells.

XX Sequence 47 BP; 9 A; 21 C; 7 G; 10 T; 0 other;

alignment\_scores:  
 Quality: 39.00 Length: 12  
 Ratio: 3.900 Gaps: 0  
 Percent Similarity: 83.333 Percent Identity: 66.667

alignment\_block:  
 US-09-439-311-2 x AAV56429/rev ..

Align seg 1/1 to reverse of: AAV56429 from: 1 to: 47

seq\_name: /SIDS2/gcdata/geneseq/geneseqn/NA1999.DAT:AAV21884

seq\_documentation\_block:  
 ID AAV21884 standard; DNA; 47 BP.  
 XX  
 AC AAX21884;  
 XX  
 DT 14-MAY-1999 (first entry)

DE Primer for antibody against ICAM-R.

XX ICAM: immunoglobulin-like loop; intercellular adhesion molecule receptor;  
 KW alpha d/CD18; antibody; immunisation; inflammatory response; asthma;  
 KW tumour growth; viral infection; therapy; primer; ss.

XX Synthetic.

OS Mus sp.

XX USS880268-A.

XX 09-MAR-1999.

PP 07-JUN-1995; 95US-0483932.

XX 05-AUG-1994; 94US-0286754.

PR 27-JAN-1992; 92US-0827689.

PR 26-MAY-1992; 92US-0889724.

PR 05-JUN-1992; 92US-0884061.

PR 22-JAN-1993; 93US-0009266.

PR 26-JAN-1993; 93US-0500787.

PR 05-AUG-1993; 93US-0102852.

PR 07-JUN-1995; 95US-0483932.

PA (ICOS-) ICOS CORP.

XX Gallatin WM, Vazeux R;

XX WPT; 1989-204041/17.

DR New intercellular adhesion molecule receptor (ICAM-R) specific  
 PT antibodies - useful for modulating ligand/receptor binding and  
 PT biological activities involving ICAM-R, especially those of the  
 PT specific and non-specific immune systems

XX Example 13; Column 41; 108pp; English.

CC This sequence is a primer for DNA encoding an antibody specific for  
 CC ICAM-R. The invention relates to antibodies (Ab) which bind specifically  
 CC to the intercellular adhesion molecule receptor (ICAM-R), inhibiting the  
 CC interaction between ICAM-R and alpha d/CD18. Abs with specific ICAM-R  
 CC binding are useful in compositions for immunisation and for purifying  
 CC ICAM-R polypeptides and identifying cells expressing ICAM-R on their cell  
 CC surface, modulating ligand/receptor binding and biological activities  
 CC involving ICAM-R, especially inflammatory responses of the specific  
 CC immune system, the non-specific immune system, monitoring and treating  
 CC asthma, tumour growth, and/or metastasis, and viral infection (e.g. HIV  
 CC infection). In particular diseases involving an essential T cell  
 CC activation (e.g. asthma, psoriasis, diabetes, graft vs. host disease,  
 CC tissue transplant rejection, and multiple sclerosis) may be treated with  
 CC anti-ICAM-R antibodies. The Abs specifically bind to and identify ICAM-R  
 CC and disrupt ICAM-R to cell adhesion molecule, especially alpha d/CD18

XX Sequence 47 BP; 9 A; 21 C; 7 G; 10 T; 0 other;

alignment\_scores:  
 Quality: 39.00 Length: 12  
 Ratio: 3.900 Gaps: 0  
 Percent Similarity: 83.333 Percent Identity: 66.667

alignment\_block:  
 US-09-439-311-2 x AAV21884/rev ..

Align seg 1/1 to reverse of: AAV21884 from: 1 to: 47

seq\_name: /SIDS2/gcdata/geneseq/geneseqn/NA1999.DAT:AAV69197

seq\_documentation\_block:  
 ID AAV69197 standard; DNA; 47 BP.  
 XX  
 AC AAV69197;  
 XX  
 DT 17-FEB-1999 (first entry)

DE Humanised ICR-1.1 antibody V<sub>k</sub> region DNA mutating oligo 110.

XX Intercellular adhesion molecule polypeptide; ICAM-R; humanised; ICR 1.1;  
 KW ICR 8.1; monoclonal antibody; therapeutic; inflammatory; asthma; tumour;  
 KW graft-versus-host disease; viral infection; toxin; radionuclide;  
 KW neovascularisation site; mutagenic; PCR primer; ss.

XX Synthetic.

OS Mus sp.

PN US5837822-A.

PP 17-NOV-1998.

XX 07-JUN-1995; 95US-0487113.

PR 07-JUN-1995; 95US-0487113.

PR 27-JAN-1992; 92US-0827689.

PR	26-MAY-1992;	92US-0889724-
PR	05-JUN-1992;	92US-0894061-
PR	22-JAN-1993;	93US-0002666-
PR	26-JAN-1993;	93WO-US00787-
PR	05-AUG-1993;	93US-010852-

(ICOS-) ICOS CORP.

WPI: 1999-0233535/03.  
GALLATIN MM, Vazquez

卷之三

## Humanised antibodies

Digitized by srujanika@gmail.com

Example 13; Column 42; 116pp; English.

The invention relates to humanised ICR 1.1 and ICR 8.1 antibodies

The invention relates to humanised ICR 1.1 and ICR 8.1 antibodies targeted to the human intercellular adhesion molecule polypeptide (ICAM-R) polypeptide. Antibodies specific for ICAM's are potentially useful as therapeutic compounds, for treating e.g. immune-mediated inflammatory conditions (e.g. graft-versus-host disease), asthma, tumours or viral infections. Monoclonal antibodies specific for ICAM-R, or their conjugates formed with e.g. toxins or radionuclides are useful for therapeutically targeting or detecting neovascularisation sites. PCR mutagenic Oligos AAV9197 and AAV9198 are used in the construction of the VK region of the humanised antibody ICR-1.1.

alignment scores:

Quality: 39.00 Length: 12  
Ratio: 3.900 Gaps: 0  
Percent Similarity: 83.333 Percent Identity: 66.667  
alignment\_block:  
US-09-439-311-2 x AAV69197/rev ..

US-09-439-311-2

Allan seg 1/1 to reverse of:

Allan seg 1/1 to reverse of:

卷之三

44 AGGATGGAGACTGGGTCAGCACGATTGGGAGTGGAA 9





J., DeFord,J., McFarland,J., Burzinski,K., Khan,M., Kupfer,K. and Garner,H.R.  
 TITLE Genomic Sequence Sampled Map of Chromosome 11  
 JOURNAL Unpublished (1996)  
 COMMENT Contact: Evans GA, Shane Probst,  
 McDermott Center for Human Growth and Development  
 University of Texas Southwestern Medical Center At Dallas  
 5323 Harry Hines Blvd, Dallas TX 75235-6591  
 Tel: 214-668-1600  
 Fax: 214-668-1666  
 Email: gevans@utsouthwestern.edu, shane@mcdermott.swmed.edu  
 Seq primer: T7  
 Class: cosmid ends  
 High quality sequence stop: 60.  
 Location/Qualifiers  
 FEATURES source  
 1. .60  
 /organism="Homo sapiens"  
 /clone\_id="CSRL-2591"  
 /clone\_lib="CSRL flow sorted Chromosome 11 specific  
 cosmid"  
 /sex="Female"  
 /cell\_type="chimeric hamster somatic cell hybrid"  
 /note\_vector: scos-1; Human Chromosome 11 specific cosmid  
 library prepared from flow sorted human Chromosome 11  
 derived from Chinese Hampster Ovary (CHO) monochromosomal  
 somatic cell hybrid, J1."  
 BASE COUNT ORIGIN  
 16 a 16 c 5 g 22 t 1 others  
 alignment\_block:  
 US-09-439-311-2 x B04096 ..  
 Align seg 1/1 to: B04096 from: 1 to: 60  
 seq\_name: gb\_gss:A2469793  
 seq\_documentation\_block:  
 LOCUS A2469793 44 bp DNA GSS 04-OCT-2000  
 DEFINITION 1M0283F04R Mouse 10kb plasmid UGGC1M library Mus musculus genomic  
 ACCESSION A2469793  
 VERSION A2469793.1 GI:10627918  
 KEYWORDS GSS.  
 SOURCE house mouse.  
 ORGANISM Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 REFERENCE 1 (bases 1 to 44)  
 AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,  
 Islam,H., Monga,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly  
 ,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.,  
 and Wright,D., Weiss,R.  
 TITLE Mouse whole genome scaffolding with paired end reads from 10kb  
 Plasmid inserts  
 JOURNAL Unpublished (2000)  
 COMMENT Contact: Robert B. Weiss  
 University of Utah Genome Center  
 University of Utah

---

Rn. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT  
 84112, USA  
 Tel: 801 585 5506  
 Fax: 801 585 7177  
 Email: ddunn@genetics.utah.edu  
 Insert Length: 10000 Std Error: 0.00  
 Plate: 0283 row: F column: 04  
 Seq primer: CACAGGAAACGCTAAGACC  
 Class: plasmid ends  
 High quality sequence stop: 44.  
 Location/Qualifiers  
 FEATURES source  
 1. .44  
 /organism="Mus musculus"  
 /strain="C57BL/6J"  
 /ab\_xref="Taxon:0090"  
 /clone\_id="UUGC1M0283F04"  
 /clone\_label="Mouse 10kb plasmid UGGC1M library"  
 /sex="Male"  
 /lab\_host="E. Coli strain XL10-Gold, T1-resistant, F-"  
 /note="Vector: PMD4-znv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (<http://www.Jax.org/resources/documents/dnars/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD2 (gigaT2114gb1AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance." (Stratagene) cells  
 BASE COUNT ORIGIN  
 9 a 12 c 12 g 11 t  
 alignment\_scores:  
 Quality: 39.00 Length: 13  
 Ratio: 3.545 Gaps: 0  
 Percent Similarity: 84.615 Percent Identity: 53.846  
 alignment\_block:  
 US-09-439-311-2 x A2469793 ..  
 Align seg 1/1 to: A2469793 from: 1 to: 44  
 seq\_name: gb\_est1.AU107968  
 seq\_documentation\_block:  
 LOCUS AU107968 50 bp mRNA EST 05-APR-2001  
 DEFINITION AU107968 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone KAT1118, mRNA sequence.  
 ACCESSION AU107968  
 VERSION AU107968.1 GI:13557490  
 KEYWORDS EST.  
 SOURCE human.  
 ORGANISM Homo Sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 50)  
 AUTHORS Suzuki,Y., Tsunoda,T., Taira,H., Mizushima-Sugano,J., Sese,J., Hata  
 ,H., Ota,T., Isogai,T., Tanaka,T., Nakamura,Y., Morishita,S., Okubo  
 ,K., Suyama,A. and Sugano,S.



/cultivar="mixed background W23/A188/B73"  
 /db\_xref="taxon:4577"  
 /clone\_1kb="006 - Rescuemu Grid G"  
 /tissue\_type="leaf"  
 /dev\_stage="adult"  
 /lab\_host="DH10B"  
 /note="Organ: leaf; Vector: Rescuemu (engineered from pBlueScript backbone); Site,1: BamHI; Site,2: BglII;  
 Rescuemu is a 4.9 kb, modified maize Mu transposon designed to allow plasmid rescue from total genomic DNA. Mu elements insert preferentially into transcription units. For more information on Rescuemu, go to the web site, [www.zmudb.iastate.edu/](http://www.zmudb.iastate.edu/) and follow the links for Rescuemu. Grid G was grown at Stanford in 2000. DNA was extracted from leaf punches, double digested using BamHI and BglII, and ligated to form circular plasmids. DH10B cells were transformed and then screened on LB plates with ampicillin.

BASE COUNT	13 a	18 c	7 g	19 t
ORIGIN				

alignment\_scores:  
 Quality: 39.00 Length: 11  
 Ratio: 4.333 Gaps: 0  
 Percent Similarity: 81.818 Percent Identity: 54.545

alignment\_block:  
 Align seg 1/1 to reverse of: AZ921603 from: 1 to: 57  
 US-09-439-311-2 x AZ921603/rev ..

seq\_name: gb\_gss:AZ998589

seq\_documentation\_block:  
 LOCUS AZ998589 54 bp DNA GSS 27-APR-2001  
 DEFINITION clone UGGC2M0285D08 R, DNA sequence.  
 ACCESSION AZ998589  
 VERSION AZ998589.1 GI:13869816  
 KEYWORDS GSS.  
 SOURCE house mouse.  
 ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 REFERENCE I (bases 1 to 54)  
 AUTHORS Dunn,D., Avagaj,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenem,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts  
 Unpublished (2000)  
 Contact: Robert B. Weiss  
 University of Utah Genome Center

JOURNAL COMMENT

BASE COUNT	11 a	2 c	21 g	20 t
------------	------	-----	------	------

alignment\_scores:  
 Quality: 38.50 Length: 18  
 Ratio: 2.750 Gaps: 1  
 Percent Similarity: 77.778 Percent Identity: 50.000

alignment\_block:  
 Align seg 1/1 to: AZ998589 from: 1 to: 54  
 US-09-439-311-2 x AZ998589 ..

seq\_name: gb\_est1:AU106648

seq\_documentation\_block:  
 LOCUS AU106648 50 bp mRNA EST 05-APR-2001  
 DEFINITION Sugano Homo sapiens cDNA library Homo sapiens cDNA clone KAT05523 mRNA sequence.  
 ACCESSION AU106648  
 VERSION AU106648.1 GI:15556169  
 KEYWORDS EST.  
 SOURCE human.

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrini; Hominidae; Homo.  
 REFERENCE I (bases 1 to 50)  
 AUTHORS Suzuki,Y., Tsunoda,T., Taira,H., Mizushima-Sugano,J., Sese,J., Hata,H., Ota,T., Israei,T., Tanaka,T., Nakamura,Y., Morishita,S., Okubo,K., Sugama,A. and Sugano,S.

TITLE Fine structural analysis of transcription start sites of human mRNAs using full-length enriched and 5'-end enriched cDNA libraries

JOURNAL Unpublished (2001)  
 COMMENT Contact: Yuraku Suzuki  
 Department of Virology  
 Institute of Medical Science, University of Tokyo  
 4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan  
 Email: [ysuzuki@ims.u-tokyo.ac.jp](mailto:ysuzuki@ims.u-tokyo.ac.jp)  
 FEATURES source  
 High quality sequence stop: 54.  
 Location/Qualifiers 1..54  
 /organism="Mus musculus"

,S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).

## FEATURES source

1. .50

/organism="Homo sapiens"

/db\_xref="taxon:9606"

/clone\_lib="Sugano Homo sapiens cDNA library"

BASE COUNT	10 a	20 c
ORIGIN	8 g	12 t

## alignment\_scores:

Quality: 38.00

Length: 16

Gaps: 0

Percent Identity: 56.250

## alignment\_block:

US-09-439-311-2 x AU106648/rev

## Align seg 1/1 to reverse of: AU106648 from: 1 to: 50

247 GlnAspPheAlaLeuAsnGlyValValleGlyLysValAspTyrSer 262

49 CAGCTGCAGCTGTCAAGTAGACTGCAAAGGGAGCTAGACATTG 2

seq\_name: gb\_est2:C20861

## seq\_documentation\_block:

HUMGS0004926 Human adult (K.Okubo) Homo sapiens cDNA 3', mRNA

sequence.

ACCESSION C20861

VERSION C20861.1

KEYWORDS EST.

SOURCE

ORGANISM

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrate; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 56)

AUTHORS Okubo,K.

TITLE Bodymap: human gene expression database

COMMENT Unpublished (1995)

Contact: Okubo,K.

Institute for Molecular and Cellular Biol

1-3,Yamada-oka, Suita, Osaka Pref. 565, Japan

Email: kousaku@imcb.osaka-u.ac.jp

Human Gene Signature, 3'-directed cDNA sequence. We are not submitting the same cDNA sequence redundantly to DBAJ since 1993's

For the abundance information of clones with this sequence in this library and as well as in other 3'-directed libraries, see ,  
<http://www.imcb.osaka-u.ac.jp/bodymap/>. The sequences of the clones represented by this GS sequences is also found there.

## FEATURES source

1. .56

/organism="Homo sapiens"

/db\_xref="taxon:9606"

/clone\_lib="Human adult (K.Okubo)"

/dev\_stage="adult" 9 c 7 g

BASE COUNT 19 a

ORIGIN 9 c 7 g

## alignment\_scores:

Quality: 38.00

Length: 18

Gaps: 0

Percent Identity: 44.444

## alignment\_block:

US-09-439-311-2 x C20861/rev ..

Align seg 1/1 to reverse of: C20861 from: 1 to: 56

215 GluGluIleAsnArgAsnAlaAspLySThrGlyLysArgAlaThrPheR 231
:         :      :      :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :   :

231 pVal 232
54 GACAGATATTCATACTAGTGTCACGTGTTAAGATTCTNNTTGA 5

4 GATC 1

## seq\_name: gb\_gss:AZ654882

seq_documentation_block:
57 bp DNA
LOCUS AZ654882
DEFINITION clone UGGCIM052N22 F, DNA sequence.
REFERENCE 14-DEC-2000
VERSION A2654882
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
REFERENCE Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenah,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenah,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
VERSION A2654882.1
TITLE GI:11792028
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
UNIVERSITY University of Utah Genome Center
ADDRESS Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
PHONE Tel: 801 585 5606
FAX: 801 585 7177
EMAIL: ddunn@genetics.utah.edu
INSERT LENGTH: 10000 Std Error: 0.00
PLATE: 0529 row: N column: 22
SEQ PRIMER: CGRTGTAACACGAGGCCGT
CLASS: plasmid ends
HIGH QUALITY SEQUENCE STOP: 57.
LOCATION/QUALIFIERS 1. .57

/organism="Mus musculus"
/strain="C57BL/6J"
/clone="UGGCIM052N22"
/clone.lib="Mouse plasmid UGGCIM library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-
/note="Vector: pD42nv; Puriified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.Jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pD42 (9147321149b) AEF29072.1, a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

16 a 23 c 6 g 12 t

## ORIGIN

alignment\_scores:  
 Quality: 38.00 length: 14  
 Ratio: 3.800 gaps: 0  
 Percent Similarity: 71.429 Percent Identity: 42.857

alignment\_block:  
 US-09-439-311-2 x AZ654882/rev

Align seq 1/1 to reverse of: AZ654882 from: 1 to: 57

seq\_name: gb.est1.AA628048

seq\_documentation\_block:

LOCUS AA628048 60 bp mRNA EST 31-OCT-1997  
 DEFINITION nci-cgap.s1 NCI-CGAP\_Ov6 Homo sapiens cDNA clone IMAGE:1154625  
 similar to gb:U07857 14 KD PROTEIN OF SIGNAL RECOGNITION PARTICLE  
 (HUMAN); mRNA sequence.

ACCESSION AA628048  
 VERSION AA628048.1 GI:2540047  
 KEYWORDS EST.  
 SOURCE human.

ORGANISM Homo sapiens  
 Hukaryota; Metazoa; Chordata; Craniata; Vertebrates; Euteleostomi;  
 Mammalia; Buterzia; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 60)  
 NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.  
 \* AUTHORS Rodriguez F., Chuquidi, M.D., Michael R. Emmert-Buck, M.D., Ph.D.  
 TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),  
 Tumor Gene Index  
 JOURNAL Unpublished (1997)  
 COMMENT Contact: Robert Strausberg, Ph.D.  
 Email: cgabsx@mail.nih.gov  
 Tissue Procurement: Andrew Beckchuck, M.D., Elise Kohn, M.D.,  
 Rodrigo F. Chuquidi, M.D., Michael R. Emmert-Buck, M.D., Ph.D.  
 CDNA Library Preparation: David B. Krizman, Ph.D.  
 CDNA Library Arrayed by: Greg Lennon, Ph.D.  
 DNA Sequencing by: Washington University Genome Sequencing Center  
 Clone distribution: NCI-CGAP clone distribution information can be  
 found through the I.M.A.G.E. Consortium/LINL at:  
[www-bio.lnl.gov/bbrp/image/image.html](http://www-bio.lnl.gov/bbrp/image/image.html)

Trace considered overall poor quality

Insert Length: 300 Std Error: 0.00  
 Seq primer: -40m13 fwd. ER from Amersham  
 High quality sequence stop: 1.

FEATURES source

source  
 /organism="Homo sapiens"  
 /obj\_xref="txon:9606"  
 /clone="IMAGE:1154625"  
 /clone\_id="NCI-CGAP\_Ov6"  
 /sex="Female"  
 /tissue\_type="normal cortical stroma"  
 /lab\_host="BHL10"  
 /note="Organ: ovary; Vector: pAM10; mRNA made from normal ovarian cortical stroma; CDNA made by oligo-dT priming. Non-directionally cloned. Size-selected on agarose gel, average insert size 600 bp."

BASE COUNT ORIGIN  
 alignment\_scores:  
 Quality: 38.00 Length: 12  
 Ratio: 3.455 Gaps: 0  
 Percent Similarity: 91.667 Percent Identity: 58.333

alignment\_scores:  
 Quality: 38.00 Length: 12  
 Ratio: 3.455 Gaps: 0  
 Percent Similarity: 91.667 Percent Identity: 58.333

alignment\_block:  
 US-09-439-311-2 x AA628048 ..

Align seq 1/1 to: AA628048 from: 1 to: 60

seq\_name: gb\_gss:AA29558

seq\_documentation\_block:

LOCUS AA29558 33 bp DNA GSS 03-OCT-2000  
 DEFINITION 1M0213A18R Mouse 10kb plasmid UGGC1M library Mus musculus genomic  
 clone UGGC1M0213A18, DNA sequence.

ACCESSION AA29558  
 VERSION AA29558.1 GI:10553671  
 KEYWORDS GSS.

SOURCE house mouse.  
 ORGANISM Mus musculus  
 Hukaryota; Metazoa; Chordata; Craniata; Vertebrates; Euteleostomi;  
 Mammalia; Buterzia; Rodentia; Sciurognathii; Muridae; Murinae; Mus.  
 REFERENCE 1 (bases 1 to 33)  
 AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacon,T., Dival,B., Hamil,C.,  
 Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,  
 M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.,  
 and Wright,D., Weiss,R.  
 TITLE Mouse whole genome scaffolding with paired end reads from 10kb  
 plasmid inserts  
 JOURNAL Unpublished (2000)  
 COMMENT Contact: Robert B. Weiss  
 Email: ddunn@genetics.utah.edu  
 University of Utah Genome Center  
 University of Utah  
 Km. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT  
 Tel: 801 585 5606  
 Fax: 801 585 7177  
 Insert length: 10000 Std Error: 0.00  
 Plate: 0213 row: A column: 18  
 Seq primer: CACCAAGAACAGCTTGA  
 Class: Plasmid ends  
 High quality sequence stop: 33.  
 FEATURES source  
 source  
 /strain="C57BL/6J"  
 /obj\_xref="Taxon:1090"  
 /clone="UGGC1M0213A18"  
 /clone\_id="Mouse 10kb plasmid UGGC1M library"  
 /sex="Male"  
 /lab\_host="E. Coli strain XL10-Gold, T1-resistant, F-"  
 /note="Vector: PW242uv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource  
 (<http://www.Jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pW42 (<http://www.Jax.org/Ar129072.1>), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold ("Stratagene) cells and selected for ampicillin resistance."

BASE COUNT ORIGIN  
 alignment\_scores:  
 Quality: 38.00 Length: 12  
 Ratio: 3.455 Gaps: 0  
 Percent Similarity: 91.667 Percent Identity: 58.333



